Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Biomedicine & Pharmacotherapy 149 (2022) 112787

Available online 8 March 2022
0753-3322/© 2022 The Author(s). Published by Elsevier Masson SAS. This is an open access article under the CC BY license

REVIEW

Traditional Chinese medicine against COVID-19: Role of the gut microbiota

Zhihua Yang a,1, Yangxi Liu c,d,1, Lin Wang c,d,1, Shanshan Lin c,d, Xiangdong Dai a,b, Haifeng Yan e, Zhao Ge c,d, Qiuang Ren c,d, Hui Wang d, Feng Zhu c, Shuping Wang f,*

1 State Key Laboratory of Component-Based Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China
2 Institute of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China
3 Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China
4 First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300381, China
5 The First Affiliated Hospital of Henan University of Traditional Chinese Medicine, Zhengzhou, Henan 450000, China
6 Characteristic Medical Center of Chinese People’s Armed Police Force, Tianjin 300162, China

ARTICLE INFO

Keywords:
COVID-19
Traditional Chinese medicine
Gut microbiota
SARS-CoV-2
ACE2
Cytokine storm

ABSTRACT

Coronavirus disease 2019 (COVID-19) is an acute respiratory infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and it has become a public health concern worldwide. In addition to respiratory symptoms, some COVID-19 patients also show various gastrointestinal symptoms and even consider gastrointestinal symptoms to be the first manifestation. A large amount of evidence has shown that SARS-CoV-2 infection could disrupt the gut microbiota balance, and disorders of the gut microbiota could aggravate the condition of COVID-19 patients. Therefore, maintaining the gut microbiota balance is expected to become a potential new therapeutic target for treating COVID-19. Traditional Chinese medicine (TCM) has significant effects in all stages of the prevention and treatment of COVID-19. It can adjust the gut microbiota and is an ideal intestinal microecological regulator. This review summarizes the advantages and clinical efficacy of TCM in the treatment of COVID-19 and expounds on the relationship between TCM and the gut microbiota, the relationship between COVID-19 and the gut microbiota, the mechanism of gut microbiota disorders induced by SARS-CoV-2, the relationship between cytokine storms and the gut microbiota, and the role and mechanism of TCM in preventing and treating COVID-19 by regulating the gut microbiota to provide new research ideas for TCM in the prevention and treatment of COVID-19.

1. Introduction

In late December 2019, several health institutions reported patients with unexplained pneumonia related to epidemiology in Wuhan, Hubei Province, China. On January 7, 2020, Chinese scientists isolated the pathogenic coronavirus for the first time from respiratory tract samples of patients in Wuhan and sequenced the full length of the genome [1]. On February 11, the International Committee on Taxonomy of Viruses (ICTV) and the World Health Organization (WHO) named the virus and the disease that it caused severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease 2019 (COVID-19), respectively [2,3]. COVID-19 is extremely harmful, with the characteristics of rapid transmission, strong pathogenicity, and poor prognosis. On March 12, the WHO declared that the outbreak of COVID-19 constituted a global "pandemic" [4]. Because of the lack of drugs targeting SARS-CoV-2 specifically, as of February 26, 2022, the cumulative number of

Abbreviations: COVID-19, Coronavirus Disease 2019; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; TCM, traditional Chinese medicine; WHO, World Health Organization; CNKI, China National Knowledge Infrastructure Database; VIP, VIP Chinese Science and Technology Journal Database(VIP); CBM, Chinese Biomedical Literature Database; ARDS, acute respiratory distress syndrome; MODS, multiple organ dysfunction syndromes; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; IL, interleukin; CK, creatine kinase; CK-MB, creatine kinase-myocardial band; LDH, lactate dehydrogenase; BUN, blood urea nitrogen; ALT, alanine aminotransferase; AST, aspartate aminotransferase; Scr, serum creatinine; TNF, tumor necrosis factor; MERS-CoV, middle east respiratory syndrome coronavirus; ACE2, angiotensin-converting enzyme 2; TMPRSS2, transmembrane protease serine 2; G-SCF, granulocyte colony-stimulating factor; SCFAs, short-chain fatty acids.

* Correspondence to: Characteristic Medical Center of Chinese People’s Armed Police Force, No. 220 Chenglin Road, Dongli District, Tianjin 300162, China.
E-mail address: yzb93510@163.com (S. Wang).
1 Zhihua Yang and Yangxi Liu contributed equally to this work.

https://doi.org/10.1016/j.biopha.2022.112787
Received 15 January 2022; Received in revised form 26 February 2022; Accepted 2 March 2022
Available online 8 March 2022
0753-3322/© 2022 The Author(s). Published by Elsevier Masson SAS. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
COVID-19 cases globally has surpassed 433 million in 216 countries, areas, and territories and more than 5.96 million confirmed deaths [5]. Although significant progress has been made in clinical and vaccine research, many countries are still experiencing or have experienced a second or third wave of the COVID-19 pandemic, mainly due to mutations of SARS-CoV-2 [6,7].

The initial symptoms of COVID-19 patients are mainly characterized by fever, fatigue, and a dry cough. Clinical studies have found that SARS-CoV-2 can also cause digestive symptoms, such as diarrhoea, abdominal pain, nausea, and vomiting [8–11]. Clinical data have shown that a considerable proportion of COVID-19 patients have symptoms related to intestinal flora disturbance, indicating that the SARS-CoV-2 virus could cause the problem of intestinal microecological imbalance, especially in critically ill patients with poor prognoses [11,12]. Compared with non-COVID-19 patients, the composition of the gut microbiota of COVID-19 patients has changed significantly, regardless of whether the patients have received medication [12,13]. Therefore, there could be a close relationship between the intestinal flora and SARS-CoV-2 infection [14]. The diagnosis and treatment of COVID-19 (8th trial edition) [15] clearly mentions that “intestinal microecological regulators could be used to maintain intestinal microecological balance and prevent secondary infection”. Studies have shown that traditional Chinese medicine (TCM) is an effective microecological regulator that has the functions of adjusting imbalances in the intestinal flora, promoting the growth of beneficial bacteria, and inhibiting the excessive reproduction of harmful bacteria. In the prevention and control of this epidemic, TCM has been deeply involved in the whole process of prevention, treatment, and rehabilitation, complementing and cooperating with Western medicine, making important contributions and playing a unique role in the comprehensive control of the COVID-19 epidemic [16]. We performed the comprehensive retrieval of electronic databases in both Chinese and English (the China National Knowledge Infrastructure Database(CNKI), VIP Chinese Science and Technology Journal Database(VIP), WangFang Database, Chinese BioMedical Literature Database (CBM), PubMed and Embase) for collecting the published research from inception to December 10, 2021. Eventually, we summarized 69 representative clinical trials, including 19 randomized, controlled trials (RCTs), 24 retrospective cohort studies (RCSs), 10 case-control studies (CCSs), and 16 others. This review mainly summarizes the clinical efficacy of TCM in the prevention and treatment of COVID-19; the relationship between the gut microbiota and TCM; COVID-19, SARS-CoV-2, and inflammatory storms; and how TCM regulates the gut microbiota to prevent and treat COVID-19 to provide new strategies and new targets for the prevention and treatment of COVID-19.

2. The advantages of TCM for COVID-19

COVID-19 has the characteristics of rapid onset, strong infectivity, and easy spread. It belongs to the category of “dampness toxin epidemic” in TCM, and the main nature of the disease is as a dampness toxin. According to the theory of TCM, the disease is mainly located in the lungs and spleen. The basic pathogenesis is “dampness, toxin, heat, phlegm, blood stasis and deficiency” [17–20]. Early clinical manifestations of the disease can include fever or no fever, and fever is often accompanied by multiple symptoms of hiding fever, dry coughing, fatigue, vomiting, loose stools, diarrhoea, and other digestive symptoms. The tongue coating is generally greasy and has obvious dampness toxicity from the disease [21]. In the whole clinical process, attention must be paid to eliminating dampness, resolving turbidity, eliminating filth and removing toxicity, as well as the effects of blood stasis [19]. TCM has been used to treat epidemic diseases since ancient times and has accumulated abundant successful experience in the prevention and treatment of epidemic diseases for thousands of years [22–24]. The advantage of TCM is that, even if the cause of the disease is unknown, a set of corresponding prescriptions can be proposed based on the clinical symptoms under the guidance of the theory of syndrome differentiation and treatment, which can relieve clinical symptoms, shorten the course of the disease, and prevent deterioration due to the disease [25,26].

3. Clinical efficacy of TCM in the prevention and treatment of COVID-19

In the prevention and treatment of COVID-19, TCM is an irreplaceable main force [27]. Zhang et al. [28] reported that early treatment with TCM could reduce the inflammatory response, regulate immune function, promote the absorption of pulmonary inflammation, and reduce mortality in patients with severe COVID-19. The integration of traditional Chinese and Western medicine had a good effect on COVID-19, and it could improve the rate of alleviation of fever, coughing, expectoration, fatigue, chest tightness, and anorexia; shorten the duration of fever and coughing; shorten the hospital stay; reduce the severity of illness; promote the absorption of pulmonary inflammation and nucleic acid negative conversion; and improve the overall response rate and cure rate [29–43].

We independently searched the clinical trials of TCM treating COVID-19 in the relevant databases, including the CNKI, VIP, Wanfang Database, CBM, PubMed, and Embase. The search time was from inception to December 10, 2021. On the one hand, the following terms for COVID-19 were adopted: “novel coronavirus pneumonia”, “new coronary pneumonia”, “NCP”, “New Coronavirus”, “2019 novel coronavirus”, “COVID-19”, “2019-nCoV”, “coronavirus disease 2019”, “coronavirus disease-19”, “severe acute respiratory syndrome coronavirus 2”, and “SARS-CoV-2”. On the other hand, the search terms for TCM mainly included “traditional Chinese medicine”, “Chinese medicine”, “Chinese and Western medicine”, and “prescription”. A total of 69 representative clinical trials, including 19 randomized, controlled trials (RCTs), 24 retrospective cohort studies (RCSs), 10 case-control studies (CCSs), and 16 others, were completed and summarized [38,44–48,50–67,69–93,95,97–112,114–116]. According to the available clinical data, there have been many clinical trials on the clinical advantages of TCM in the prevention and treatment of COVID-19, including suspected stages, mild stages, moderate stages, severe stages, critical stages, and convalescent stages, as shown in Fig. 1. The clinical evidence for TCM for COVID-19 is summarized in Table 1. In addition, the relationship of TCM with its constituents is depicted in Fig. 2.

For suspected COVID-19 patients: 1) Lianhua Qingwen granules [44, 45] and Xiaochaihu decoction combined with Yupingfeng powder [46] significantly improved the clinical symptoms of fever, cough, phlegm, fatigue, and shortness of breath; Lianhua Qingwen granules [45] relieved gastrointestinal symptoms; and 2) Xiaochaihu decoction combined with Yupingfeng powder [46] reduced the level of C-reactive protein (CRP) and improved lung CT imaging. For asymptomatic COVID-19 patients, Chaihu Ganlu decoction [47] and Lianzhang Jiedu oral liquid [48] could shorten the nucleic acid negative conversion time and hospital stay and prevent deterioration due to the disease.

COVID-19 patients have the most typical clinical symptoms of fever, coughing, and fatigue. Therefore, alleviating these clinical symptoms is crucial for the prevention and treatment of COVID-19 [49]. For mild or moderate COVID-19 patients: 1) Qingfei Paidu decoction [50], Lianhua Qingwen granules [51–53], Jinling Qinggan granules [54], Shufeng Jiedu capsules [55,56], Maxing Shigan decoction [57], Xiyanping injection [58], Jinebi oral liquid [59], Huoxiang Zhengqi [60], Toujie Quwen granules [61], Jinqiang Xuanfei Jiedu mixture [62], Ganlu Xiaodu decoction [63], Lianhua Qingke granules [64], Jinyinhua oral liquid [65], and Sanxiaoyin modified and subtracted prescription [66] alleviated the main clinical symptoms of fever, coughing, and fatigue; Lianhua Qingwen granules [52], Ganlu Xiaoou decoction [68], Lianhua Qingke granules [64], Jinyinhua oral liquid [65,67], and Jinye Baidu granules [68] reduced the rate of conversion from mild or moderate cases to severe or critical cases; 2) Lianhua Qingwen granules [69], Qingfei Paidu decoction [50], Shufeng Jiedu capsules [55], Maxing Shigan decoction [57], Reduning injection [70], Xiyanping injection
Severe or critical COVID-19 patients have the main factors directly affecting mortality. Treating severe cases is crucial since they can easily develop into critical cases, or the patients can even eventually die without timely and effective treatment. The Diagnosis and Treatment Protocol for COVID-19 (trial version 8 revision) formulated by the National Health Commission of the People’s Republic of China, pointed out that, in severe cases, dyspnoea and/or hypoxemia usually occur one week after disease onset, and some severe patients have rapid progression to acute respiratory distress syndrome (ARDS), septic shock, refractory metabolic acidosis, coagulation disorders, and multiple organ failure. Therefore, to reduce the mortality rate of COVID-19, it is necessary to apply more active and effective treatments to prevent the development of COVID-19. For severe or critical COVID-19 patients: 1) Qingfei Paidu decoction [38,83], Xuebijing injection [84,85], Shenhuan granules [86], Lung-toxin Dispelling Formula No.1 [87], and Huashi Baidu decoction [88] improved the survival rate and prevented deterioration due to the disease; Xuebijing injection [84] and Reduning injection [89] shortened the length of intensive care unit (ICU) hospitalization; 2) Qingfei Paidu decoction [38], Huashi Baidu granules [90] Reduning injection [89], Xuebijing injection [84,85], "Fei Yan No. 1" [91], and Danggui Shaoyao powder [92] shortened the time of nucleic acid negative conversion; 3) Qingfei Paidu decoction [38,83], Xuebijing injection [84,85], Shenhuang granules [86], "Fei Yan No. 1" [91], and Danggui Shaoyao powder [92] promoted the absorption of pulmonary inflammation and improved chest CT imaging; and 3) Qingfei Paidu decoction [38,83], Xuebijing injection [84,85], "Fei Yan No. 1" [91], and Danggui Shaoyao powder [92] shortened the time of nucleic acid negative conversion and improved the ratio of nucleic acid negative conversion.

For the clinical treatment period (mild, moderate, severe, and critical COVID-19 patients): 1) Lianhua Qingwen granules [96], Qingfei Paidu decoction [97–101], Xuanfei Baidu decoction [102], Huashi Baidu granules [103], Xuankang granules prescription [104], and sodium chloride injection [105] relieved the clinical symptoms of fever, coughing, fatigue, chest tightness and loss of appetite; Gegen Qinlian pills [106] improved the clinical symptoms of coughing, chest tightness,
| NO | Name of traditional Chinese medicine | Compositions | Type of study | Location of study | Intervention | Control | Severity classification | Treatment duration | Main findings | References |
|----|-------------------------------------|--------------|--------------|------------------|--------------|---------|------------------------|-------------------|--------------|-----------|
| 1  | BuZhong Yiqi decoction (BZYQ)       | Huangqi (Astragali Radix), Renshen (Ginseng Radix Et Rhizoma), Gancao (Glycyrrhiza Radix Et Rhizoma), Baizhu (Atractylodis Macrocephalae Rhizoma), Chenpi (Giri Reticulatae Pericarpium), Danggui (Angelicae Sinensis Radix), Shengma (Gimirufugae Rhizoma), Chaihu (Bupleuri Radix) | Case-control studies(CCS) | Hubei 672 Orthopedic Hospital of Integrated Traditional Chinese and Western Medicine | BZYQ + C (n=36) | WMST (n=35) | Mild cases | 10d | (1) Improve the clinical symptoms (2) Shorten the course of disease and improve the cure rate (3) Decrease the levels of CRP, ESR | [75] |
| 2  | Chaihu Ganlu decoction (CHGL)       | Chaihu (Bupleuri Radix), Huangqin (Scutellariae Radix), Shichangpu (Acori Tatarinowii Rhizoma), Guang Huoxiang (Pogostemonis Herba), Doukou (Amomi Fructus Rotundus), Lianqiao (Forysthiae Fructus), Nansha Shen (Adenophorae Radix), Yi Yi Rene (Coicis Semen), Houpo (Magnoliae Oficinalis Cortex), Fuling (Poria), Banxia (Pinelliae Rhizoma), Chenpi (Giri Reticulatae Pericarpium), Chantui (Cicadae Periostracum), Jiangcan (Bombyx Batricatus), Kuxingren (Armeniaceae Seman Amarum), Jiegeng (Platyodonis Radix), Maiya (Hordei Fructus Germinatus) | Before and after comparison | People’s Hospital of Wanzhou District of Chongqing | CHGL + WMST (n=46) | Asymptomatic cases | 5-22d | (1) Prevent deterioration of the disease (2) Shorten nucleic acid negative time (3) Improve chest CT imaging (4) Increase lymphocyte count | [47] |

(continued on next page)
| NO | Name of traditional Chinese medicine | Compositions | Type of study | Location of study | Intervention | Control | Severity classification | Treatment duration | Main findings | References |
|----|-------------------------------------|--------------|---------------|------------------|--------------|---------|-------------------------|------------------|--------------|------------|
| 3  | Danggui Shaoyao power (DGSY)        | Danggui (Angelicae Sinensis Radix), Baihao (Paenoniae Radix Alba), Chuanxiong (Chuanxiong Rhizoma), Baizhu (Atractylodis Macrocephalae Rhizoma), Zexie (Alismatis Rhizoma), Fuling (Poria) | Before and after comparison | Wuhan Union Hospital | DGSY + WMST (n=100) | WMST (n=100) | Severe cases | 10d | (1) Relieve the symptoms fever, cough, fatigue, dry cough, chest tightness and shortness of breath. (2) Improve the ratio of nucleic acid negative conversion (3) Improve chest CT imaging (4) Reduce the levels of CRP, ALT, AST and increase lymphocyte count | [92] |
| 4  | Ganlu Xiaodu decoction (GLXD)       | Huashi (Talcum), Yinchen (Artemisiae Scopariae Herba), Huangqin (Scutellariae Radix), Shichuangpu (Acori Tatarinowii Rhizoma), Mutong (Akeiae Caulis), Chuanbeimu (Fritillariae Cirrhosae Bulbus), Guanghuoxiang (Pogostemonis Herba), Doukou (Amomi Fructus Rotundus), Lianqiao (Forsythiae Fructus), Bohe (Menthae aplocalycis Herba), Shegan (Belamcandae Rhizoma), Shanyao (Dioscoreae Rhizoma), Gancao (Glycyrrhizae Radix Et Rhizoma) | Retrospective cohort studies (RCS) | Wuhan Third Hospital | GLXD + C (n=115) | WMST (n=115) | Moderate cases | 7-14d | (1) Improve the clinical symptoms of fever, cough, expectoration, chest tightness, fatigue, panting and shortness of breath. (2) Shorten hospitalization time and improve the cure rate. (3) Reduce the rate of severe cases worsening (4) Promote absorption of lung inflammation and improve chest CT imaging (5) Decrease the levels of CRP, PCT and increased lymphocyte count | [63] |
| 5  | Gegen Qinlian pill (GGQL)           | Huangqin (Scutellariae Radix), Huanglian (Gopidis Rhizoma), Gegen (Puerariae Lobatae Radix), Gancao (Glycyrrhizae Radix Et Rhizoma) | CCS | Hubei Provinicial Hospital of traditional Chinese medicine | GGQL + C (n=58) | WMST (n=60) | All cases | 7-14d | (1) Improve clinical symptoms of cough, chest tightness, nausea, vomiting and loose stool. (2) Shorten the time of nucleic acid negative conversion (3) Decrease the levels of hs-CRP and increase lymphocyte count | [106] |
| NO | Name of traditional Chinese medicine | Compositions | Type of study | Location of study | Intervention | Control | Severity classification | Treatment duration | Main findings | References |
|----|-------------------------------------|--------------|---------------|-------------------|--------------|---------|------------------------|------------------|--------------|------------|
| 6  | Huashi Baidu granule (HSBD + C)    | Mahuang (Ehedraep Herba), Kuxingren (Armeniacae Seman Amarum), Shigao (Gypsum Fibrosatum), Gancao (Glycyrrhizae Radix Et Rhizoma), Guanghuaxiang (Pogostemonis Herba), Houpo (Magnoliaceae Officinalis Cortex), Cangzhu (Atractylodis Rhizoma), Caoguo (Tsaooko Fructus), Banxia (Pinelliae Rhizoma), Fuling (Poria), Dahuang (Rhei Radix Et Rhizoma), Huangqi (Astragali Radix), Tinglizi (Descurainiae Semen Lepidii Semen), Chishao (Paeoniae Radix Rubra) | RCS | Wuhan Jinyintan Hospital | HSBD + C (n=23) | WMST (n=32) | Severe cases | 16d | (1) Promote the absorption of pulmonary inflammation and improved chest CT imaging (2) Decrease the levels of CRP, ESR, serum ferritin, and myoglobin | [90] |
|    | Randomized controlled trials(RCT) |             |               |                   |              |         |                        |                  |              |            |
|    | TheThird People’s Hospital of Yichang |             |               |                   |              |         |                        |                  |              |            |
|    | CCS |             |               |                   | HSBD + C (n=25) | WMST (n=25) | Severe cases | 15d | (1) Relieve the clinical symptoms of fever, cough, fatigue, chest tightness, loss of appetite (2) Promote the absorption of pulmonary inflammation or improve chest CT imaging (3) Reduce the levels of CRP and ESR | [103] |

(continued on next page)
| NO | Name of traditional Chinese medicine | Compositions | Type of study | Location of study | Intervention | Control | Severity classification | Treatment duration | Main findings | References |
|----|----------------------------------|--------------|---------------|------------------|--------------|---------|------------------------|------------------|--------------|-----------|
| 7  | HuoXiang Zhengqi power (HXZQ)    | Guanghuoxiang (Pogostemonis Herba), Cangzhu (Atractylodis Rhizoma), Chenpi (Citri Reticulatae Pericarpium), Fabanxia (Pinelliae Rhizoma Praeparatum), Fuling (Poria), Houpo (Magnoliae Officinalis Cortex), Jiegeng (Platycodonis Radix), Gancao (Glycyrrhizae Radix Et Rhizoma) | Before and after comparison | The Red Cross Hospital of Yulin | HXZQ + WMST (n=11) | Moderate cases | 9-33d | (1) Improve clinical symptoms of fever, fatigue, cough, dizziness (2) Improve clinical cure rate (3) Reduce the rate of severe cases worsening (4) Reduce the levels of CRP, ESR, PCT, and LDH | [60] |
| 8  | Jiawei Yupingfeng powder (YPF)   | Huangqi (Astragali Radix), Baizhu (Atractylodis acrocephalae Rhizoma), Fangfeng (Saponshikoviae Radix), Fuling (Poria), Cangzhu (Atractylodis Rhizoma), Guanghuoxiang (Pogostemonis Herba), Zisugeng (Perillae Caulis), Banxia (Pinelliae Rhizoma), Sharen (Amomi Fructus), Shengjiang (Zingiberis Rhizoma Recens) | RCS | The Third People’s Hospital of Jiujiang | YPF + C (n=30) WMST (n=24) | Mild or Moderate cases | 14d | (1) Improve the clinical symptoms (2) Shorten nucleic acid negative time and hospitalization time (3) Decrease the levels of hs-CRP, ESR and increase lymphocyte count | [73] |
| 9  | Jinbei oral liquid (JBOL)        | Huangqi (Astragali Radix), Dangshen (Codonopsis Radix), Beishashen (Glehniae Radix), Danshen (Salviae Miltiorrhizae Radix Et Rhizoma), Danggui (Angelicae Sinensis Radix), Chuanxiong (Chuanxiong Rhizoma), Jinyinhua (Lonicerae Japonicae Flos), Lianqiao (Forsythiae Fructus), Huangqin (Scutellariæ Radix), Chuansheimu (Fritillariae Cirrhosae Bulbus), Banxia | RCS | The Third Hospital of Wuhan | JBOL + C (n=50) WMST (n=46) | Mild or Moderate cases | 15 d | (1) Relieve clinical symptoms of fever, fatigue, cough (2) Reduce the abnormal fluctuation of body temperature during the treatment (3) Improve the ratio of nucleic acid negative conversion | [59] |
| NO | Name of traditional Chinese medicine | Compositions | Type of study | Location of study | Intervention | Control | Severity classification | Treatment duration | Main findings | References |
|----|--------------------------------------|--------------|---------------|------------------|--------------|---------|-------------------------|------------------|--------------|------------|
| 10 | Jinhua Qinggan granules (JHQG)       | Pinelliae Rhizoma, Gancao (Glycyrrhizae Radix Et Rhizoma), Jinyinhua (Lonicerae Japonicae Flos), Shigao (Gypsum Fibrosum), Niubangzi (Arctii Fructus), Zhebeimu (Fritillariae Thunbergii Bulbus), Kuxingren (Armeniacae Semen Amarum), Mahuang (Ehedraep Herba), Huangqin (Scutellariae Radix), Lianqiao (Forsythiae Fructus), Qinghao (Artemisiae Annuae Herba), Zhihu (Anemarrhenae Rhizoma), Bohe (Menthae Aplocalycis Herba), Gancao (Glycyrrhizae Radix Et Rhizoma) | CCS | Hubei Provinical Hospital of Integrated Traditional Chinese and Western Medicine | JHQG + C (n=82) | WMST (n=41) | Mild cases | 5d | (1) Alleviate the clinical symptoms of fever, cough, fatigue, expectoration and anxiety | [54] |
| 11 | Jinqiang Xuanfei Jiedu mixture (JQXF) | Scrophulariae Radix, Jinyinhua (Lonicerae Japonicae Flos), Lianqiao (Forsythiae Fructus), Kuxingren (Armeniacae Semen Amarum), Chenpi (Citri Reticulatae Pericarpium), Doukou (Amomi Fructus Rotundus), Huangqin (Scutellariae Radix), Shegan (Belamcandae Rhizoma), Bohe (Menthae Aplocalycis Herba), Gancao (Glycyrrhizae Radix Et Rhizoma) | RCS | Beijing YouAn Hospital Affiliated to Capital Medical University | JHQG + C (n=44) | WMST (n=36) | Moderate or Severe cases | 7d | (1) Shorten the length of hospitalization or nucleic acid negative time (2) Promote the absorption of pulmonary inflammation or improve chest CT imaging | [110] |
|    |                                       | (continued on next page) | Wuhan Union Hospital | JQXF + C (n=99) | WMST (n=60) | Mild or Moderate cases | 7d | (1) Improve clinical symptoms of fever, cough, sore throat, loss of appetite. (2) Reduce inflammatory reaction | [62] |
| NO | Name of traditional Chinese medicine | Compositions | Type of study | Location of study | Intervention | Control | Severity classification | Treatment duration | Main findings | References |
|----|------------------------------------|--------------|---------------|------------------|--------------|---------|------------------------|------------------|--------------|------------|
| 12 | Jinyinhua oral liquids (JYH)       | Jinyinhua (Lonicerae Japonicae Flos) | CCS           | The First People’s Hospital of Jiangxia District | JYH+C (n=100) | WMST (n=100) | Mild or Moderate cases | 10d              | (1) Shorten nucleic acid negative time and hospitalization time (2) Improve chest CT imaging (3) Reduce the rate of severe cases worsening | [67]        |
|    |                                    | Herba), Fangfeng (Saposhnikoviae Radix), Chaishu (Bupleuri Radix), Banlangen (Isatidis Radix), Gancao (Glycyrhizae Radix Et Rhizoma), Banxia (Pinelliae Rhizoma), Jiegeng (Platycodonis Radix), Sangbaipi (Mori Cortex), Baibu (Stemonae Radix) | | | | | | | | |
| 13 | Lanxiang Jiedu oral liquid (LXJD)  | Guanghuoxiang (Pogostemonis Herba), Peilan (Eupatorii Herba), Cangzhu (Atractyloidis Rhizoma), Houpo (Magnoliae Officinalis Cortex), Chenpi (Citri Reticulatae Pericarpium), Shengjiang (Zingiberis Rhizoma Recens), Fuling (Poria), Banxia (Pinelliae Rhizoma), Jinyinhua (Lonicerae Japonicae Flos), | CCS           | The Fifth Hospital of Shijiazhuang | LXJD+C (n=8)  | WMST (n=8)   | Asymptomatic cases    | 7d               | (1) Improve the ratio of nucleic acid negative conversion (2) Shorten hospitalization time | [48]        |
|    |                                    |              |               |                  |              |         |                        |                  |              |            |
| NO | Name of traditional Chinese medicine | Compositions | Type of study | Location of study | Intervention | Control | Severity classification | Treatment duration | Main findings | References |
|----|--------------------------------------|--------------|---------------|------------------|--------------|---------|-------------------------|------------------|--------------|------------|
| 14 | Lianhua Qingke granule (LHQK)        | Lianqiao (Forsythiae Fructus), Mianmuangzhong (Dryopteridis Crassirhizomatis Rhizoma), Taoren (Persicae Semen), Jiegeng (Platycodonis Radix), Gancao (Glycyrrhizae Radix Et Rhizoma) | RCT | Tangshan Infectious Diseases Hospital; The Third People’s Hospital of Hengshui City; Cangzhou People’s Hospital | LHQK + C (n=32) | WMST (n=25) | Mild or Moderate cases | 14d | (1) Improve the symptoms of fever, fatigue, dry pharynx and sore throat. (2) Shorten the duration of cough and expectoration symptoms. (3) Promote the absorption of pulmonary inflammation and improve chest CT imaging. (4) Reduce the rate of severe cases worsening | [64] |
| 15 | Lianhua Qingwen granules (LHQW)      | Jinyinhu (Lonicerae Japonicae Flos), Dahuang (Rhei Radix Et Rhizoma), Shigao (Gypsum Fibrosum), Lianqiao (Forsythiae Fructus), Mianmuangzhong (Dryopteridis Crassirhizomatis Rhizoma), Taoren (Persicae Semen), Jiegeng (Platycodonis Radix), Gancao (Glycyrrhizae Radix Et Rhizoma), Niuzaibai (Arctii Fructus), Jiegeng (Platycodonis Radix), Gancao (Glycyrrhizae Radix Et Rhizoma) | RCT | Puren Hospital Affiliated to Wuhan University of Science and Technology; The Ninth Hospital of Wuhan; CR & WISCO General Hospital, Wuhan University of Science and Technology | LHQW + C (n=51) | WMST (n=51) | Moderate cases | 7d | (1) Improve clinical symptoms including fever, fatigue, cough, expectoration, shortness of breath, chest distress and appetite loss. (2) Enhance the effective rate of cardinal symptom. (3) Reduce the proportion of normal to heavy | [52] |

(continued on next page)
| NO | Name of traditional Chinese medicine | Compositions | Type of study | Location of study | Intervention | Control | Severity classification | Treatment duration | Main findings | References |
|----|-------------------------------------|--------------|---------------|-------------------|--------------|---------|-------------------------|--------------------|--------------|------------|
| CCS | CR & WISCO General Hospital Affiliated to Wuhan University of Science and Technology | LHQW + C (n=63) WMST (n=38) | Pediatric cases | 10d | (1) Relieve clinical symptoms including fever, fatigue, cough, short breath (2) Improve the disappearance rates of short breath and moist crackles | [44] |
| RCS | Xiangyang No.1 People’s Hospital | LHQW + C (n=42) WMST (n=41) | Pediatric cases | 5d | (1) Improve symptoms of fever, cough, phlegm, shortness of breath, and gastrointestinal symptoms | [45] |
| RCS | The Ninth Hospital of Wuhan; CR & WISCO General Hospital, Wuhan University of Science and Technology | LHQW + C (n=21) WMST (n=21) | Moderate cases | Unreported | (1) Improve the clinical symptoms of fever, cough, expectoration and shortness of breath | [53] |
| Before and after comparison | The Puren affiliated Hospital of Wuhan University of Science and Technology | LHQW + WMCT (n=54) | Moderate cases | 7d | (1) Relieve clinical symptoms of fever, weakness, and cough, and reducing their duration Decrease the levels of ESR and D-dimer Increase the levels albumin and hemoglobin lymphocyte count relieve the clinical symptoms of fever, cough, fatigue, chest tightness, loss of appetite Shorten the length of hospitalization or (continued on next page) | [51] |
| RCS | Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology | LHQW + C (n=90) WMST (n=150) | Moderate cases | 5-7d | (1) Relieve clinical symptoms of fever, cough, shortness of breath, and fatigue and reducing their duration Increase the levels of ESR and D-dimer Increase the levels albumin and hemoglobin lymphocyte count relieve the clinical symptoms of fever, cough, fatigue, chest tightness, loss of appetite Shorten the length of hospitalization | [79] |
| RCS | Ruijin Hospital and Tongji Hospital | LHQW + C (n=113) WMST (n=49) | Moderate or Severe cases | Unreported | (1) Relieve clinical symptoms of fever, cough, shortness of breath, and fatigue and reducing their duration Increase the levels of ESR and D-dimer Increase the levels albumin and hemoglobin lymphocyte count relieve the clinical symptoms of fever, cough, fatigue, chest tightness, loss of appetite Shorten the length of hospitalization | [69] |
| NO. | Name of traditional Chinese medicine | Compositions | Type of study | Location of study | Intervention | Control | Severity classification | Treatment duration | Main findings | References |
|-----|--------------------------------------|--------------|---------------|-------------------|--------------|---------|------------------------|-------------------|--------------|------------|
| 16  | Lung-toxin dispelling formula No.1 (LDF1) | Renshen (Ginseng Radix Et Rhizoma), Jingjie (Schizonepetae Herba), Fengfang (Vespae Nidus), Jinyinhu (Lonicerae Japonicae Flos), Lianqiao (Forsythiae Fructus), Zaojiaozi (Gleditsiae Spina), Xuanshen (Scrophulariae Radix), Kuxingren (Armeniacae Semen Amaranum), Gancao (Glycyrrhizae Radix Et Rhizoma) | Before and after comparison | Zhumadian City of Chinese medicine Hospital and The First Affiliated Hospital of Henan University of Chinese Medicine | LDF1 + WMST (n=6) | Severe or Critical cases | nucelar acid negative time (3) Improve chest CT imaging (1) Promote the absorption of pulmonary inflammation (2) Shorten nucleic acid negative time | [87] |
| 17  | Maxing Shigan decoction (MXS) | Mahuang (Ehedraep Herba), Kuxingren (Armeniacae Semen Amaranum), Shigao (Gypsum Fibrosum), Gancao (Glycyrrhizae Radix Et Rhizoma) | Before and after comparison | Chongqing Three Gorges Central Hospital | MXS + WMST (n=40) | Moderate cases | 3d (1) Relieve the main clinical symptoms of fever, cough, and fatigue (2) Shorten nucleic acid negative time (3) Decrease the levels of CRP, ALT, AST, and Scr, and increase CD4+ T and CD8+ T count | [57] |
| 18  | Pneumonia No.1 (PN1) | Huangqin (Scutellariae Radix), Binglang (Arecae Semen), Zhimu (Anemarrhenae Rhizoma), Ranzia (Pinelliae Rhizoma), Danshen (Codonopsis Radix), Baihu (Paonieae Radix Alba), Gancao (Glycyrrhizae Radix Et Rhizoma), Chaibu (Bupleuri Radix), Chenpi (Citri Reticulatae Pericarpium), Houpo (Magnoliae Officinalis Cortex), Guailou (Trichonanthis) | RCS | Hubei Provincal Hospital of Traditional Chinese medicine and Hanchuan People’s Hospital | PN1 + C(n=47) WMST (n=40) | Moderate or Severe cases | Unreported (1) Shorten the time of nucleic acid negative conversion (2) Relieve the clinical symptoms | [91] |
| NO | Name of traditional Chinese medicine | Compositions | Type of study | Location of study | Intervention | Control | Severity classification | Treatment duration | Main findings | References |
|----|--------------------------------------|--------------|---------------|-------------------|--------------|---------|------------------------|-------------------|-------------|-----------|
| 19 | Qingfei decoction (QFD) | Fructus), Caoguo (Tsaooko Fructus), Huizhang (Polygoni Cuspidati Rhizoma Et Radix) | Before and after comparison | Wuhan Jiangxia Fangcang Shelter Hospital | QFD + WMST (n = 152) | Mild or Moderate cases | 14d | (1) Relieve the symptoms fever, cough, fatigue, dry cough, and chest tightness (2) Improve the ratio of nucleic acid negative conversion (3) Improve chest CT imaging (4) Reduce the rate of severe cases worsening (5) play an auxiliary role in reducing blood pressure | [74] |
| 20 | Qingfei Paidu decoction (QFPD) | Gancao (Glycyrrhizae Radix Et Rhizoma), Kuxingren (Armeniaceae Seman Anarum), Shigao (Gypsum Fibrosum), Guizhi (Cinnamomum Ramulus), Zexie (Alismatis Rhizoma), Zhuling (Polyporus), Baizhu (Atractylodis Macrocephalae Rhizoma), Fuling (Poria), Shanyao ( Dioscoreae Rhizoma), Chaihu (Bupleuri Radix), Huangqin (Scutellariae Radix), Banxia (Pinelliae Rhizoma), Ganjiang (Zingiberis Rhizoma), Guanghaoxiang (Pogostemonis Herba), Ziwan (Asteris Radix Et Rhizoma), Kuandonghua (Farfarae Flos), Shegan (Belamcandae Rhizoma), Xixin (Asari Radix Et Rhizoma), Zhishi | RCS Department of Traditional Chinese Medicine,Union Hospital,Tongji Medical College,Huazhong University of Science and Technology | QFPD + C (n = 12) | WMST (n = 12) | Severe or Critical cases | 7d | (1) Prevent early and mid term cytokine storm and improve clinical symptoms (2) Decrease the levels of CRP, IL-2R, IL-6, IL-10, and TNF-a | [83] |

(continued on next page)
| NO | Name of traditional Chinese medicine | Compositions | Type of study | Location of study | Intervention | Control | Severity classification | Treatment duration | Main findings | References |
|----|-------------------------------------|--------------|---------------|------------------|--------------|---------|-------------------------|-------------------|--------------|-----------|
| RCS | Xiangyang No. 1 People’s Hospital, affiliated hospital of Hubei University of Medicine | (Aurantii Fructus Immaturus), Chenpi (Citri Reticulatae Pericarpium) | QFPD + C (n=37) | WMST (n=26) | Mild or Moderate cases | 6d | (1) Reduce the levels of CRP, CK, CK-MB, LDH, and BUN (2) Mitigate the extent of multi-organ impairment |
| RCS | The First Affiliated Hospital of Anhui University of Traditional Chinese Medicine | QFPD + WMST (n=782) | All cases | Unreported | (1) Improve the cure rate (2) Shorten duration of hospital stay | |
| CCS | Wuchang Makeshift Hospital; Jingkai Makeshift Hospital; Jianghan Makeshift Hospital; Xinzhou Makeshift Hospital; Quankou Makeshift Hospital | QFPD + WMST (n=96) | QFPD (n=96) | Mild or Moderate cases | Unreported | (1) Shorten nucleic acid negative time and hospitalization time (2) Improve chest CT imaging |
| RCS | East Hospital of Renmin Hospital of Wuhan University | QFPD + C (n=43) | WMST (n=46) | All cases | 15d | (1) Shorten nucleic acid negative time and hospitalization time (2) Decrease the level of IL-6 and increase CD3 count |
| Before and after comparison | Infectious Disease Hospital of Heilongjiang Province; The First Hospital of Suihua City; Harbin Infectious Hospital; Jincheng People’s Hospital; Mudanjiang Kangan Hospital; Suining Central Hospital; The Affiliated Traditional Chinese Medicine Hospital of Southwest Medical University; Xingtai Hospital of Traditional Chinese Medicine; Chengde Hospital of Traditional Chinese Medicine; Yongwu Hospital, People’s Hospital of Guangxi Zhuang Autonomous Region | QFPD + WMST (n=50) | Severe cases | 6d | (1) Relieve the symptoms fever, cough, fatigue, dry cough, anorexia and asthma (2) Shorten nucleic acid negative time and hospitalization time (3) Promote the absorption of pulmonary inflammation (4) Reduce the levels of ESR, CRP, ALT, AST, and PCT and |

(continued on next page)
| NO | Name of traditional Chinese medicine | Compositions | Type of study | Location of study | Intervention | Control | Severity classification | Treatment duration | Main findings | References |
|----|----------------------------------|--------------|--------------|------------------|--------------|---------|----------------------------|-------------------|--------------|------------|
|    |                                  |              |              |                   | QFPD + WMST  | All cases | 6d                         |                   | increase WBC and lymphocyte count  | [96]       |
|    |                                  |              |              |                   | (n = 119)    |          | (1) Relieve the symptoms fever, cough, fatigue, dry cough, anorexia and asthma  |                   |              |            |
|    |                                  |              |              |                   |              |          | (2) Shorten nucleic acid negative time and hospitalization time  |                   |              |            |
|    |                                  |              |              |                   |              |          | (3) Promote the absorption of pulmonary inflammation  |                   |              |            |
|    |                                  |              |              |                   |              |          | (4) Reduce the levels of CRP and LDH, and increase lymphocyte count  |                   |              |            |
|    |                                  |              |              |                   | (n = 157)    |          | (1) Relieve the symptoms fever, cough, fatigue, and asthma  | [97]             |              |            |
|    |                                  |              |              |                   |              |          | (2) Shorten nucleic acid negative time and hospitalization time  |                   |              |            |
|    |                                  |              |              |                   |              |          | (3) Promote the absorption of pulmonary inflammation  |                   |              |            |
|    |                                  |              |              |                   | (n = 49)     |          | (1) Relieve the symptoms fever, cough, fatigue  | [101]             |              |            |
|    |                                  |              |              |                   |              |          | (2) Shorten nucleic acid negative time  |                   |              |            |
|    |                                  |              |              |                   | (n = 124)    |          | (1) Relieve the symptoms fever, cough, fatigue, dry cough and asthma  | [100]             |              |            |
|    |                                  |              |              |                   |              |          | (2) Shorten nucleic acid negative time  |                   |              |            |
|    |                                  |              |              |                   |              |          | (3) Promote the absorption of pulmonary inflammation  |                   |              |            | (continued on next page)
| NO | Name of traditional Chinese medicine | Compositions | Type of study | Location of study | Intervention | Control | Severity classification | Treatment duration | Main findings | References |
|----|-------------------------------------|--------------|---------------|------------------|--------------|---------|------------------------|------------------|--------------|-----------|
| 21 | Qingfei Touxie Fuzheng recipe (QFTX) | Mahuang (Ehedraep Herba), Shigao (Gypsum Fibrosum), Kutxingen (Armeniacae Seman Amarum), Jinjinhu (Lonicerae Japonicae Flos), Lianqiao (Forsythiae Fructus), Lugan (Phragmitis Rhizoma), Yiying (Coicis Semen), Jiangcan (Bombyx Batryticas), Chantui (Cicadae Periostracum), Huizhang (Polygoni Cuspidati Rhizoma Et Radix), Jianghuang (Curcumae Longae Rhizoma), Baishao (Paeoniae Radix Alba), Taizishen (Pseudostellariae Radix), Gancao (Glycyrrhizae Radix Et Rhizoma) | RCT | General Hospital of Central Theater Command of Chinese People’s Liberation Army | QFTX + C (n=51) | WMST (n=49) | All cases | 10d | (1) Alleviate the symptoms of fever, cough, expectoration, chest tightness, shortness of breath (2) Promote the absorption of pulmonary lesions, improve oxygenation (3) Decrease the levels of ESR, CRP, and IL-6 | [112] |
| 22 | Qingre KangDu oral liquid (QRKD) | Shigao (Gypsum Fibrosum), Banlanget (Isatidis Radix), Shengma (Cimicifugae Rhizoma) | CCS | The Fifth Hospital of Shijiazhuang | QRKD + C (n=11) | WMST (n=11) | Moderate cases | 10d | (1) Improve clinical symptoms, fever, cough, fatigue, lung disease absorption rate > | [48] |

(continued on next page)
| NO | Name of traditional Chinese medicine | Compositions | Type of study | Location of study | Intervention | Control | Severity classification | Treatment duration | Main findings | References |
|----|--------------------------------------|--------------|---------------|------------------|--------------|---------|------------------------|------------------|--------------|------------|
| 23 | Reduning injection (RDN)             | Guanghuoxiang (Pogostemonis Herba), Pugongying (Taraxaci Herba), Huanglian (Coptidis Rhizoma), Mudanpi (Moutan Cortex), Baiamaogen (Imperatae Rhizoma) | RCT          | Lianyungang Fourth People’s Hospital affiliated to Kangda College, Nanjing Medical University and The Third People’s Hospital of Yichang | RDN + C (n = 27) | WMST (n = 23) | Mild cases             | 14d              | 50% and shorten the duration of fever | [70]        |
| 24 |                                     | Qinghao (Artemisiae Annuae Herba), Jinyinhua (Lonicerae Japonicae Flos), Zhizi (Gardeniae Fructus) | RCS          | The second Affiliated Hospital of Chongqing Medical University | RDN + C (n = 32) | WMST (n = 26) | Severe cases           | 5-7d             | (1) Relieve the symptoms fever, fatigue, cough, wheezes, and sputum (2) Shorten nucleic acid negative time and hospitalization time (3) Improve chest CT imaging | [89]        |
| 25 | Sanxiaoyin modified and subtracted prescription (SXY) | Caoguo (Tsaoko Fructus), Houpo (Magnoliae Officinalis Cortex), Huangqin (Scutellariae Radix), Baishao (Paeoniae Radix Alba), Zhimu (Anemarrhenae Rhizoma), Gancao (Glycyrrhizae Radix Et Rhizoma), Dahuang (Rhei Radix Et Rhizoma), Jiangcan (Bombys Batryticatus), Chantui (Cicadae Periostracum), Mumianhua (Gossampini Flos), Niuxi (Achyranthis Bidentatae Radix) | RCS          | The Second Hospital of Jingzhou | SXY + C (n = 26) | WMST (n = 26) | Mild or Moderate cases | 7d               | (1) Alleviate the clinical symptoms of fever, cough, fatigue, dry throat, anorexia, poor mental state, and poor sleep quality (2) Shorten the average hospitalization duration (3) Improve chest CT imaging (4) Decrease the levels of CRP, ESR, and PCT, and increase lymphocyte count | [66]        |
| NO | Name of traditional Chinese medicine (abbrevations) | Compositions | Type of study | Location of study | Intervention | Control | Severity classification | Treatment duration | Main findings | References |
|----|--------------------------------------------------|--------------|---------------|------------------|--------------|---------|-------------------------|-------------------|--------------|------------|
| 26 | Shengmai injection (SM)                          | Hongshen (Ginseng Radix Et Rhizoma Rubra), Maidong (Ophiopogonis Radix), Wuweizi (Schisandrae Chinensis Fructus) | RCT           | HuBei 672 Orthopedic Hospital of Integrated Traditional Chinese and Western Medicine | Shengmai (SM) + C(n=34) | WMST (n=30) | Moderate or Severe cases | 7d | (1) Improve the symptoms of dry throat, thirst, fatigue and night sweat (2) Promote the absorption of pulmonary inflammation and improve oxygen saturation (3) Shorten the time of nucleic acid negative conversion | [93] |
| 27 | Shenhuang granule (SHG)                          | Renshen (Ginseng Radix Et Rhizoma), Dahuang (Rhei Radix Et Rhizoma), Pugongying (Taraxaci Herba), Fu zi (Aconiti Lateralis Radix Praeparata), Shuizhi (Hirudo), Daxueteng (Sargentoidea Caulis) | RCT           | Leishenshan Hospital of Wuhan, Tongji Hospital, Wuhan Mental Health Center, and Huangshi Hospital of TCM. | Shenhuang granule (SHG) + C(n=57) | WMST (n=54) | Severe or Critical cases | 14d | (1) Improve survival rate and prevent deterioration of the disease (2) Promote the absorption of pulmonary inflammation and improve chest CT imaging | [86] |
| 28 | Shuanghuanglian oral liquid (SHL)                | Jinyinhua (Lonicerae Japonicae Flos), Huangqin (Scutellarias Radix), Lianqiao (Forsythiae Fructus) | RCT           | Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology ect. | Shuanghuanglian oral liquid (SHL) + C(n=176) | WMST (n=59) | All cases | 14d | (1) Shorten nucleic acid negative time (2) Promote the absorption of pulmonary inflammation or improved chest CT imaging (3) Reduce the level of NT-proBNP | [109] |
| 29 | Shufeng Jiedu capsule (SFJD)                     | Huzhang (Polygoni Cuspidati Rhizoma Et Radix), Lugun (Phragmites Rhizoma), Chaihu (Bupleuri Radix), Lianqiao (Forsythiae Fructus), Baijiangcao (Isatidis Radix), Gancao (Glycyrrhizae Radix Et Rhizoma) | RCS           | Bozhou People’s Hospital | Shufeng Jiedu capsule (SFJD) + C(n=40) | WMST (n=30) | Mild or Moderate cases | 10d | (1) Alleviate dry cough, nasal congestion, runny nose, sore throat, fatigue, and diarrhea (2) Shorten the time of nucleic acid negative conversion | [55] |

(continued on next page)
| No | Name of traditional Chinese medicine | Compositions | Type of study | Location of study | Intervention | Control | Severity classification | Treatment duration | Main findings | References |
|----|--------------------------------------|--------------|--------------|------------------|--------------|---------|------------------------|-----------------|--------------|------------|
| 29 | Sodium Chloride Injection (SCI)      | Before and after comparison Jingzhou Hospital of Infectious Disease (Chest Hospital) of Hubei Province | Before and after comparison SCI + WMST (n=40) | All cases | Unreported | (1) Alleviate the clinical symptoms of fever, cough, fatigue, and loss of appetite (2) Shorten the length of hospitalization and nucleic acid negative time (3) Promote the absorption of pulmonary inflammation and improved chest CT imaging (4) Decrease the levels of hs-CRP, PCT, ALT, AST, and LDH, and increase lymphocyte count | [105] |
| 30 | Tanreqing Capsule (TRQ)              | RCS Shanghai Public Health Clinical Center | TRQ + C(n=25) WMST (n=57) | Mild or Moderate cases | Unreported | (1) Shorten nucleic acid negative time or hospitalization time (2) Increase the level of CD3+ T cells | [71] |
| 31 |                                    |              |              |                  |              |         | (continued on next page) |
| NO | Name of traditional Chinese medicine | Compositions | Type of study | Location of study | Intervention | Control | Severity classification | Treatment duration | Main findings | References |
|----|-------------------------------------|--------------|---------------|------------------|--------------|---------|------------------------|-------------------|--------------|-----------|
| 32 | Toujie Quwen granules (TJQW)        | Lianqiao (Forsythiae Fructus), Shancigu (Cremastrae Pseudobulbus Pleiones Pseudobulbus), Jinjinhua (Lonicerae Japonicae Flos), Huangqin (Scutellariae Radix), Daqingye (Isatidis Folium), Chaohu (Bupleuri Radix), Qinghao (Artemisiae Annuae Herba), Chantui (Cicadae Periostracum), Qianhu (Peucedani Radix), Taizishen (Pseudostellariae Radix) | RCT | Guangzhou Eighth People’s Hospital | TJQW + C (n=37) | WMST (n=36) | Mild or Moderate cases | 10d | (1) Relieve the symptoms fever, cough, fatigue, expectoration, dry pharynx and sore throat, chest tightness, (2) Reduce the rate of severe cases worsening (3) Reduce the levels of CRP and PCT and increase lymphocyte count and neutrophil ratio | [61] |
| 33 | Wuye Lugen decoction (WYLG)         | Bohe (Menthae apocalycis Herba), Guanghuoxiang (Pogostemonis Herba), Heye (Nelumbinis Folium), Peilan (Eupatorii Herba), Pipaye (Eriobotryae Folium), | Before and after comparison | Jiangmen Wuyi Hospital of Traditional Chinese Medicine Affiliated to Jinan University | WYLG + CWMT (n=18) | Convalescent cases moderate cases | (1) Relieve the symptoms fever, cough, fatigue, dry pharynx and sore throat, chest tightness (2) Improve the cure rate (3) Reduce the level of CRP and increase lymphocyte count | 15d | (continued on next page) | [80] |

(continued on next page)
| NO | Name of traditional Chinese medicine | Compositions | Type of study | Location of study | Intervention | Control | Severity classification | Treatment duration | Main findings | References |
|----|-------------------------------------|--------------|---------------|------------------|--------------|---------|-------------------------|------------------|--------------|------------|
| 34 | Xiang Hua Spray (XHS) | Lugen (Phragmitis Rhizoma), Dongguazi (Benicasae Semen) Guanghuoxiang (Pogostemonis Herba), Xiangru (Mesialis Herba), Aiye (Artemisiae Argyi Folium), Dingxiang (Caryophylli Flos), Bohe (Menfhae aplocalycis Herba), Bingpian (Borneolum) | RCT | Hubei Provincial Hospital of Traditional Chinese medicine | XHS + C(n=60) WMST (n=60) Convalescent cases | 7d | (1) Improve the total clinical efficiency (2) Alleviate the clinical symptoms of cough, chest oppression, fatigue, sweating, muscle soreness, stuffy nose and sore throat | [114] |
| 35 | Xiaochaihu decoction combined with Yupingfeng powder (XCY) | Chaihu (Bupleuri Radix), Huangqin (Scutellariae Radix), Banxia (Pinelliae Rhizoma), Mianmaguanzhong (Dryopteridis Crassirhizomatis Rhizoma), Jinyinhua (Lonicerae Japonicae Flos), Lianqiao (Forsythiae Fructus), Taizishen (Pseudostellariae Radix), Huangqi (Astragalii Radix), Fangfeng (Saposhnikoviae Radix), Baizhu (Atractylodis Macrocephalae Rhizoma), Gancao (Glycyrrhizae Radix Et Rhizoma) | RCS | Affiliated Hospital of Liaoning University of Traditional Chinese Medicine | XCY + C(n=18) WMST (n=14) Pediatric cases | 5d | (1) Improve the symptoms of fever, cough, expectoration, sore throat, shortness of breath, appetite, and chills (2) Shorten the course of fever, cough, and expectoration (3) Improve chest CT imaging | [46] |
| 36 | Xiyanping injection (XYP) | Andrographolide sulfonates | RCT | the Second Affiliated Hospital of Nanchang University ect. | XYP + C(n=65) WMST (n=65) Mild or Moderate cases | 28d | (1) Alleviate the main clinical symptoms of fever, cough, and fatigue (2) Reduce the time virus clearance (3) Shorter time to achieve negative SARS-CoV-2 RNA tests | [58] |
| 37 | Xuanfei Baidu decoction (XFBD) | Mahuang (Ebedraep Herba), Kuxingren (Armeniacae Semen Amarum), Shigao (Gypsum Fibrosum), | RCT | Wuhan Pulmonary Hospital | XFBD + C (n=22) WMST (n=22) All cases | 7d | (1) Reduce the disappearance rate of clinical symptoms such as fever, cough, (2) Reduce the rate of hospitalization (3) Reduce the rate of death | [102] |
Table 1 (continued)

| NO | Name of traditional Chinese medicine | Compositions | Type of study | Location of study | Intervention | Control | Severity classification | Treatment duration | Main findings | References |
|----|-------------------------------------|--------------|---------------|-------------------|--------------|---------|-------------------------|-------------------|--------------|-----------|
| 38 | Yuyiyiren (Coicis Semen), Cangzhi (Atractylodis Rhizoma), Guanghuoxiang (Pogostemonis Herba), Qinghao (Artemisiae Annuae Herba), Huzhang (Polygoni Cuspidati Rhizoma Et Radix), Mabiancao (Verbenae Herba), Lugen (Phragmitis Rhizoma), Tinglizi (Descurainiae Semen Lepidii Semen), Huajuhong (Citri Grandis Exocarpium), Gancao (Glycyrrhizae Radix Et Rhizoma) | Xuanfei Huazhuo prescription (XFHZ) | All cases | Before and after comparison | Affiliated Hospital of Gansu University of Chinese Medicine XFHZ \(n=40\) | WMST \(n=40\) | All cases \(8-23\text{d}\) | (1) Relieve the symptoms cough, fever, sputum, diarrhea, loss of appetite and fatigue | (2) Decrease the levels of CRP and ESR, and increase WBC and lymphocyte counts | [104] |
| 39 | Chongqing public health medical treatment center | Unreported | 14d | | | | | (1) Relieve the symptoms cough, fever, sputum, diarrhea, loss of appetite and fatigue | (2) Shorten the time of nucleic acid negative conversion | (3) Promote the absorption of pulmonary inflammation | (4) Promote WBC, lymphocyte percentage, neutrophil percentage, lymphocyte absolute value, CRP, ESR, total bilirubin (TBIL), AST/ALT and LDH to return to the normal range | [111] |
| NO | Name of traditional Chinese medicine | Compositions | Type of study | Location of study | Intervention | Control | Severity classification | Treatment duration | Main findings | References |
|---|---|---|---|---|---|---|---|---|---|---|
| Xue’s Fu Yang Zhu Shi decoction cutting (XFYZS) | Dangshen (Codonopsis Radix), Bai Zhu (Atractylodes Macrocephalae Rhizoma), Fu Ji (Aconiti Lateralis Radix Praeparata), Fuling (Poria), Houpo (Magnoliae Officinalis Cortex), Banxia (Pinelliae Rhizoma), Gan Jiang (Zingiberis Rhizoma), Chai Hu (Bupleuri Radix), Sheng Ma (Cimicifugae Rhizoma), Huang Qi (Astragali Radix), Huang Qin (Scutellariae Radix), Lugen (Phragmitis Rhizoma) | Before and after comparison | Before and after comparison | XFYZS+WMST (n=36) | | | | (1) Relieve the clinical symptoms of fever, cough, sputum, and sore throat (2) Promote the negative rate of nucleic acid (3) Improve the improvement rate of chest CT | |
| 40 | Xuebijing injection (XBJ) | Chishao (Paeoniae Radix Rubra), Hong Hua (Carthami Flos), Dang Gui (Angelicae Sinensis Radix), Chuan Xiong (Chuanxiong Rhizoma), Dan Shen (Salviae Miltiorrhizae Radix Et Rhizoma) | RCT | The First People’s Hospital of Jingzhou | XBJ+C(n=30) WMST (n=30) | Severe cases 14d | | | (1) Improve survival rate and prevent deterioration of the disease (2) Reduce the rate of mechanical ventilation, rate of septic shock, (3) Decrease the levels of IL-6, IL-8, and TNF-α and increase lymphocyte count (4) Shorten the length of ICU hospitalization stay | [84] |
| | | Chishao (Paeoniae Radix Rubra), Hong Hua (Carthami Flos), Dang Gui (Angelicae Sinensis Radix), Chuan Xiong (Chuanxiong Rhizoma), Dan Shen (Salviae Miltiorrhizae Radix Et Rhizoma) | CCS | North Hospital of the First Hospital of Changsha City | XBJ+C(n=20) WMST (n=20) | Severe cases 7d | | | (1) Reduce the rate of severe cases worsening (2) Decrease the levels of CRP, ESR, and acute physiology and chronic health evaluation II (APACHEII) score, and increase lymphocyte count | [85] |
| | | Chishao (Paeoniae Radix Rubra), Hong Hua (Carthami Flos), Dang Gui (Angelicae Sinensis Radix), Chuan Xiong (Chuanxiong Rhizoma), Dan Shen (Salviae Miltiorrhizae Radix Et Rhizoma) | RCT | Affiliated Dongfend Hospital, Hubei University of Medicine | XBJ+C(n=22) WMST (n=22) | Moderate cases 7d | | | (1) Improve the cure rate | [78] |

(continued on next page)
| NO | Name of traditional Chinese medicine | Compositions | Type of study | Location of study | Intervention | Control | Severity classification | Treatment duration | Main findings | References |
|----|--------------------------------------|--------------|---------------|------------------|--------------|---------|-------------------------|--------------------|--------------|------------|
| 41 | Yidu-toxicity blocking lung decoction (YTBL) | Kuxingren (Armeniacae Seman Amarum), Shigao (Gypsum Fibrosam), Gualou (Trichosanthis Fructus), Dahuang (Rhei Radix Et Rhizoma), Mahuang (Ehedraep Herba), Tinglizi (Descurainiae Semen Lepidii Semen), Taoren (Persicae Semen), Caoguo (Tsaoko Fructus), Binglang (Atractylodis Macrocephalae) | RCT | The First Affiliated Hospital of Anhui Medical University | YTBL+C (n=15) | WMST (n=24) | Severe cases | 29d | (1) All patients are cured and discharged (2) Decrease the levels of IL-6 and TNF-α | [95] |
| 42 | Yinqiao powder combined with modified Sanren decoction (YCS) | Pugongying (Taraxaci Herba), Lugan (Phragmitis Rhizoma), Yiyiren (Coicis Semen), Jinyinhua (Lonicerae Japonicae Flos), Liangqiao (Forsythiae Fructus), Chaihu (Bupleuri Radix), Huangqin (Scutellariae Radix), Kuxingren (Armeniacae Seman Amarum), Doukou (Atractylodis Macrocephalae) | RCS | the Second Hospital of Nanjing | YCS+C(n=20) | WMST (n=16) | Moderate cases | 7d | (1) Relieve clinical symptoms such as fever, cough, fatigue, muscle soreness, dry mouth (2) Shorten the time of returning to normal body temperature (3) Increase the ratio of nucleic acid negative conversion | [76] |
| 43 | Yiqi Yangyin granules (YQYY) | Dangshen (Codonopsis Radix), Maidong (Ophiopogonis Radix), Baihe (Lilii Bulbus), Fuling (Poria), Baizhu (Atractylodis Macrocephalae) | RCT | Jiangxia Wuhan District Hospital of Traditional Chinese Medicine; The First Hospital of Wuhan; Huai’an Hospital of Traditional Chinese Medicine; Yangzhou Hospital of Traditional Chinese Medicine; The Third People’s Hospital of Zhenjiang | YQYY+C (n=30) | WMST (n=30) | Convalescent cases | 14d | (1) Alleviate the clinical symptoms of fatigue, short of breath, dry mouth, dry pharynx, vexing heat in chest, palms and soles | [115] |

(continued on next page)
Table 1 (continued)

| NO | Compositions | Type of study | Location of study | Intervention | Main finding | Reference |
|----|--------------|---------------|-------------------|--------------|--------------|-----------|
| 25 | Rhizoma), Chenpi (Citri Reticulatae Pericarpium), Maiya (Hordei Fructus Germinatus), Hehuanpi (Albiziae Cortex), Digupi (Lycii Cortex), Gancao (Glycyrrhizae Radix Et Rhizoma) | WMST: Western medicine routine symptomatic treatment. | shortened the length of hospitalization or chloride injection [105] | Improve expiratory peak flow rate value [123-125] | Increase CD3 + T cell counts | References | *(1) Improve expiratory peak flow rate value *(2) Improve expiratory peak flow rate value *(3) Improve expiratory peak flow rate value |

For convalescent COVID-19 patients, TCM can remove residual evil, help vital Qi, improve symptoms, promote the repair of injured organs and tissues, and expedite the process of rehabilitation [113]. Xiang Huo spray [114] improved the total clinical efficiency and alleviated the clinical symptoms of coughing, chest tightness, fatigue, sweating, muscle soreness, stuffy nose, and sore throat; Yiqi Yangyin granules [115] alleviated the clinical symptoms of fatigue, shortness of breath, dry mouth, vexing heat in the chest, palms, and soles, and dry pharynx; improved the expiratory peak flow rate value; and increased CD3 + T cell counts. Wuye Lugen decoction [116] could improve the clinical symptoms of fatigue, dry mouth, insomnia, and anxiety and increase lymphocyte and WBC counts and the levels of haemoglobin (HGL), CRP, and IgG.

4. The relationship between the gut microbiota and TCM

The normal gut microbiota consists of bacteria, viruses, fungi, and archaea in numbers up to $10^{13-10^{14}}$. On the one hand, under normal physiological conditions, the gut microbiota can interact with the host through complex dynamic network regulatory mechanisms, participate in regulating the host’s material metabolism and immune defence, and protect the integrity of the intestinal mucosal barrier structure [117–119]. On the other hand, beneficial bacteria can produce antibacterial substances that are more beneficial to the body and resist the invasion of pathogens by competing for nutrients and occupying favourable sites [120]. When the homeostasis of the intestinal microbiology is disrupted, harmful bacteria increase, the intestinal barrier is damaged, and the function of the immune system is disrupted, thus triggering a variety of diseases and threatening human health. It has been reported that the gut microbiota is closely related to the inflammatory response induced by novel coronaviruses and could be highly correlated with individual susceptibility to COVID-19 [121]. Numerous studies have shown that respiratory virus infection of the host causes alteration of the gut microbiota, increasing the colonization of pathogenic bacteria and decreasing the number of probiotics. In turn, alteration of the gut microbiota can reduce the level of the host’s antiviral immune response and aggravate the lung injury caused by viral infection. In addition, the gut microbiota can act directly on viruses through its structural components or metabolites or indirectly influence the body’s immune response, ultimately affecting the outcome of viral infection [122]. Probiotics can enhance the antiviral ability of the body by regulating innate immunity, maintaining the integrity of the intestinal wall, and activating adaptive immune responses [123].

There is a close relationship between TCM and gut microbiota, as...
shown in Fig. 3. On the one hand, TCM can influence the composition and metabolism of the gut microbiota; on the other hand, the gut microbiota can metabolize Chinese herbal medicinal components [124]. A large number of studies have shown that TCM can significantly adjust the alteration of the gut microbiota, promote the growth of beneficial bacteria, inhibit the overproliferation of harmful bacteria, and balance the number of these probiotic and pathogenic bacteria, thus maintaining a healthy intestinal environment [125,126]. Most TCM is administered orally and is selectively metabolized in the intestine by intestinal secretory enzymes into active or absorbable components; TCM thus exerts a therapeutic effect. In addition, the gut microbiota will be affected by TCM while transforming it. The composition of the gut microbiota will be changed under the effects of TCM. On the one hand, TCM can alleviate disease-induced gut microbiota disorders by regulating the composition of the gut microbiota and then treating the disease; on the other hand, changes in the composition of the gut microbiota can also lead to changes in its metabolic ability, thus triggering gut microbiota-mediated interactions of Chinese herbal medicinal components. The gut microbiota in the body plays an important role in the pharmacological effects of oral TCM, and TCM helps to maintain the balance of the gut microbiota. The interaction between them is of great significance in preventing and treating diseases and promoting health [127].

5. The relationship between COVID-19 and gut microbiota

The initial symptoms of COVID-19 patients are mainly fever, coughing, and fatigue. With in-depth research on the disease, it has also not been uncommon to find gastrointestinal symptoms caused by SARS-CoV-2 infection in clinical practice [128], especially in critically ill patients with poor prognoses [9–11]. Available evidence suggests that SARS-CoV-2 can directly damage the digestive system, disrupt the intestinal microecological balance, and cause associated clinical manifestations [11,129,130]. Gastrointestinal symptoms are present in approximately 2–79.1% of patients [9, 49, 131–133], and these symptoms can appear early in the onset of the disease, even earlier than fever and respiratory symptoms [134–136]. By studying 1099 patients with COVID-19, Nanshan Zhong’s team found that the clinical manifestations of gastrointestinal symptoms, such as nausea, vomiting, and diarrhea, could be 8.7%, and gastrointestinal symptoms were more common in severe patients, accounting for 12.7% [49]. Another study [9] found that 11.4% of COVID-19-infected people presented with gastrointestinal symptoms, such as abdominal pain, diarrhea, nausea, and vomiting. Moreover, a study [137] confirmed that some COVID-19 patients had their first symptoms in the digestive tract, suggesting that gastrointestinal symptoms are another major manifestation of COVID-19 patients, in addition to respiratory symptoms. The Renmin Hospital of Wuhan University reported “atypical” cases in which patients with COVID-19 presented with gastrointestinal symptoms only, without fever or respiratory symptoms [138]. Wang et al. [132] found that the proportion of COVID-19 patients with gastrointestinal symptoms as initial symptoms accounted for approximately 10.12%, and the patients only had diarrhoea symptoms at the onset of the disease, followed by fever, dyspnoea, and other symptoms. Currently, SARS-CoV-2 has been identified and isolated from the stool specimens of COVID-19 patients [139,140], and disorders of the intestinal microecology have been detected in COVID-19 patients with gastrointestinal symptoms [130]. These findings suggest that SARS-CoV-2 might cause alterations in the gut microbiota along with pulmonary infection, which could be the main reason for the nausea, vomiting, diarrhoea, and other gastrointestinal symptoms in patients.

Alteration of the gut microbiota is closely related to the severity of COVID-19 patients [11,141]. A study found that COVID-19 patients with diarrhoea were in more serious conditions and had higher rates of receiving noninvasive ventilation and transferring to the intensive care unit and a higher case fatality rate than those without diarrhoea [11, 142]. Another study that included 74 COVID-19 patients with gastrointestinal symptoms and 577 COVID-19 patients without gastrointestinal symptoms found that the proportion of COVID-19 patients with gastrointestinal symptoms who were in severe or critical condition was as high as 22.97% – higher than the 8.14% of patients without gastrointestinal symptoms [9]. In 138 COVID-19 study subjects, the incidence of gastrointestinal symptoms was higher in severely ill patients than in ordinary patients, and severely ill patients presented with abdominal pain, whereas mildly ill patients did not [143]. Numerous retrospective studies have indicated that more than half of COVID-19 patients are complicated with underlying diseases, such as diabetes mellitus, hypertension, and hyperlipidaemia, with poor tolerance and rapid disease progression, and they are prone to becoming severe and critical high-risk patients [49,131,132]. In an interview with a CCTV reporter, the academician Li Lanjuan mentioned that severe and critical COVID-19 patients mostly have gut microbiota disorders. Severe and critical COVID-19 patients are predominantly elderly patients complicated with underlying diseases [144]. The intestinal microecological stability and diversity of elderly individuals decrease, and infection with SARS-CoV-2 causes gut microbiota disorders, which tend to affect the absorption of nutrients and reduce mucosal barrier immunity; the risk of nosocomial infections is thus increased [145]. In summary, there are many links between the gut microbiota and COVID-19. On the one hand, COVID-19 patients have gut microbiota disorders and impaired barrier function; could have gastrointestinal symptoms, such as nausea, vomiting, and diarrhoea; and could also have gastrointestinal symptoms as the first manifestation. On the other hand, gut microbiota disorders can aggravate the condition of COVID-19 patients.

6. Mechanism of gut microbiota disorder induced by SARS-CoV-2

SARS-CoV-2 is the third coronavirus to emerge in humans over the past 20 years after severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) [146,147]. Studies have shown that the pathogenic process of SARS-CoV-2 infection is associated with the binding of angiotensin-converting enzyme 2 (ACE2) [129]. Current studies have shown that, similar to SARS-CoV, SARS-CoV-2 uses ACE2 with the help of transmembrane protease serine 2 (TMPRSS2) as a cellular receptor in the host cell [148–150]. There are many ACE2 proteins in alveolar epithelial cells. After SARS-CoV-2 enters alveolar epithelial cells, virus replication causes an immune response in the body, and excessive cytokine production eventually forms a cytokine storm, in turn triggering inflammation, which is an important cause of lung injury, acute respiratory distress syndrome (ARDS), and multiple organ failure or even death [25,151]. Notably, ACE2 is highly expressed not only in alveolar cells but also in oesophageal epithelial cells, gastrointestinal epithelial cells, and hepatobiliary duct cells [152–154]. The above evidence suggests that SARS-CoV-2 might not only infect the respiratory system but also directly infect the digestive system and cause related clinical manifestations [155]. The high expression of ACE2 in the intestine can regulate the composition of the gut microbiota [156]. ACE2 is necessary for the expression of the neutral amino acid transporter B0AT1 protein in intestinal epithelial cells, and it participates in the absorption of tryptophan [157]. When the level of ACE2 expression in
A cytokine storm, also known as a cytokine cascade or hypercytokinaemia, is essentially a more intense inflammatory response and an excessive immune response of the body to pathogenic microorganisms (such as bacteria and viruses) [160]. When pathogens invade the organism, a moderate immune response is activated, which can hinder viral replication and rapidly clear the pathogens. However, an excessive immune response leads to an imbalance in the immune regulatory network, and an excessive inflammatory response occurs in the body, prompting a large release of multiple inflammatory factors and cytokines into the body fluids in a short period and producing systemic inflammatory damage, resulting in lung injury, ARDS and multiple organ dysfunction syndromes (MODS) and even death [161]. Test reports of COVID-19 patients have shown that the absolute value of lymphocytes was reduced in most patients, suggesting that SARS-CoV-2 could mainly act on lymphocytes, especially T lymphocytes. The viral particles spread through the respiratory mucosa, infect other cells, induce a cytokine storm in vivo, produce a series of immune responses, and cause peripheral blood changes in immune cells, such as leukocytes and lymphocytes [131]. Clinical studies have shown that plasma levels of IL-2, IL-7, IL-10, granulocyte colony-stimulating factor (G-SCF), interferon-γ-inducible protein-10 (IP-10), monocyte chemoattractant protein-1 (MCP-1), macrophage inflammatory protein-1α (MIP-1α), and TNF-α in COVID-19 patients are elevated [131,151], and critically ill patients usually exhibit reduced peripheral blood T lymphocytes [132]. Abundant evidence has suggested that cytokine storms play an important role in the progression of COVID-19, especially in critically ill patients [11, 162,163]. A recent COVID-19 clinical study [151] showed that a high level of inflammatory cytokine expression, the ‘cytokine storm’, was found in critically ill patients infected with SARS-CoV-2, suggesting a possible correlation between cytokine storms and the severity of patients’ infections. Cytokine storms are now considered a turning point in the progression of COVID-19 patients to severe and critical illnesses. Some patients with COVID-19 had mild disease in the early stages, with sudden aggravation in the later stages and eventual death from MODS, with exacerbation mainly due to a cytokine storm [164]. Reports have indicated that the cytokine storm in severe COVID-19 patients is closely associated with severe lung pathological injury and the occurrence and development of ARDS, and it is one of the main causes of death in patients [131,151,165].

Numerous studies in recent years have shown that intestinal microorganisms play important roles in regulating the immunity of the body and that changes in the gut microbiota are closely associated with local and systemic inflammation [166]. The microecological imbalance of the gut microbiota leads to the release of inflammatory mediators caused by intestinal endotoxin and gut microbiota displacement, directly or indirectly promoting the occurrence and development of the COVID-19 inflammatory storm. After SARS-CoV-2 infection, especially in elderly patients or those with underlying diseases, alteration of the gut microbiota increases the production of various toxins, including endotoxins, and impairs intestinal barrier function, causing a large number of toxins to enter the bloodstream. These toxins can directly damage lung structure and function, or they can aggravate the systemic and pulmonary inflammatory response by inducing inflammation and creating inflammatory factor storms, leading to severe disease. It was found that, among COVID-19 patients, the elderly and those with underlying diseases, such as diabetes, hypertensive disease, coronary heart disease, and extreme obesity, are susceptible to SARS-CoV-2, are prone to developing acute and critical illness, and have a higher risk of death [132,167–169]. Previous studies [170,171] have shown that the richness, evenness, and diversity of the gut microbiota in this population were significantly reduced, and the dominant flora was significantly decreased, with an imbalance in intestinal microecology. Infection with SARS-CoV-2 further aggravates gut microbiota disorders, leading to disruption of the intestinal mucosal barrier, the release of inflammatory mediators caused by intestinal endotoxin and gut microbiota displacement, and the formation of an inflammatory factor storm to exacerbate systemic and pulmonary inflammatory responses. It is now believed that the cause of severe pneumonia is not the virus itself but the excessive immune response induced by infection. The unbalanced inflammatory factor system in the body is an important cause of pneumonia and ALI [172, 173]. The above studies suggest that the gut microbiota is closely associated with the inflammatory storm in COVID-19 patients; that is, imbalance of the gut microbiota after SARS-CoV-2 infection, disruption of the intestinal mucosal barrier, and release of inflammatory mediators caused by intestinal endotoxin and gut microbiota displacement can directly or indirectly promote the occurrence and development of the COVID-19 “inflammatory storm”.

8. TCM regulation of the gut microbiota to prevent and treat COVID-19

8.1. Regulation of gut microbiota structure

Many studies have been reported on the direct regulation of the gut microbiota composition by TCM, including the regulation of the gut microbiota by a single TCM or a single extracted component, and on the forms of Chinese herbal medicinal ingredients that act. Guo et al. [174] found that extracts of Ginseng radix et rhizome rubra and Coisem sinens could promote the growth of probiotics such as Lactobacillus and Bifidobacterium and inhibit the growth of pathogenic bacteria such as Escherichia, Staphylococcus, and Salmonella in vitro. Chang et al. [175] reported the effect of adding Ganoderma extract to the food of mice fed a high-fat diet and found that Ganoderma extract not only reduced the elevated ratio of the Firmicutes/Bacteroides phylum and the level of endotoxin-producing Proteobacteria induced by a high-fat diet but also maintained the integrity of the intestinal mucosal barrier and reduced the occurrence of endotoxaemia. The compatibility of essential oil from Atractylodis macrocephalae rhizoma and total ginsenosides reduced the relative abundance of opportunistic pathogens, such as Bacteroides, Anaerotruncus, and Desulfovibrio [176]. Dong et al. [177] found that Shenling Baizhu powder could effectively regulate antibiotic-induced gut microbiota imbalances and reduce endotoxin production by promoting the proliferation of probiotics, such as Lactobacillus and Bifidobacterium, in the intestinal tract. The single Chinese medicines Ginseng radix et rhizoma, berberine, Lonicerae japonicae flos, Rehmanniae radix praeparata, Artemisiae arigi folium, and emodin had proliferative effects on intestinal probiotics such as Lactobacillus in the gut microorganisms of different disease models [127]. HuoXiang Zhengqi [178] could
Fig. 2. The relationship of TCM with its constituents. Note: The green square nodes represent TCM. The red, yellow, and light red circular nodes represent the constituents of TCM. The size and darkness of the nodes represent the frequency of appearance of each constituent. The size from small to large and the darkness of the nodes from dark to light are illustrated in ascending order of frequency of appearance. The connecting lines indicate that each node is related. The width of the connecting lines was based on the frequency of appearance of constituents, and the colour and rule were the same as the circular nodes. JQXF: Jinqiang Xuanfei Jiedu mixture; LHQW: Lianhua Qingwen capsule; PN1: Pneumonia No.1; XBJ: Xuebijing injection; TJQW: Toujie Quwen granules; YPF: Jiawei Yupingfeng powder; GLXD: Ganlu Xiaodu decoction; XYP: Xinyanping injection; TRQ: Tanreqing injection; SHG: Shenhuang granule; YCS: Yinqiao powder combined with modified Sanren decoction; JHQG: Jinhua Qinggan granules; CHGL: Chaihu Ganlu decoction; QTF: Qingfei Touxie Fuzheng recipe; QFPDD: Qingfei Paidu decoction; SFJD: Shufeng Jiedu capsule; DGSY: Danxiang Shaoxue powder; GBQL: Gegen Qinlian pill; JBOJ: Jinbei oral liquid; SHL: Shuanghuangliang oral liquid; XFDH: Xuanfei Huazhuo prescription; SHBD: Huashi Baudu decoction; QRKD: Qingre Kangdu oral liquid; QFD: Qingfei decoction; LHQK: Lianhua Qingke granules; RDN: Reduning injection; LDF1: Lung-toxin dispelling formula No.1; BZYQ: BuZhong YiQi decoction; HXZQ: Huoxiang Zhengqi power; JYH: Jinyinhua oral liquid; LXJD: Lanxiang Jiedu oral liquid; SM: Shengmai power; XFYYS: Xue’s Fu Yang Zhu Shi decoction cutting.
support the growth of normal intestinal flora and promote the proliferation of beneficial bacteria (Bifidobacterium and Lactobacillus). Gegen Qinlian decoction could reverse the reduction in the richness of the gut microbiota, change its structure, and significantly increase the relative abundances of short-chain fatty acid (SCFA)-producing bacteria, including Akkermansia, Bacteroides, Clostridium, Ruminococcus, and Phascolarctobacterium [179]. Coptidis rhizoma extracts could improve intestinal microecology. Pathogens such as Enterobacter and Enterococcus were inhibited, and probiotics such as Lactobacilli and Bifidobacteria were notably promoted by Coptidis rhizoma extracts [180]. Fermented Yupingfeng polysaccharides exhibited greater beneficial effects in improving the gut microbiota, including augmenting flora diversity and the abundance of cellulolytic bacteria and reducing the abundance of Enterococcus spp and Streptococcus spp [181]. Based on 16S rDNA sequencing, Wu et al. [182] found that Qingfei Paidu decoction significantly modulated the composition of rat gut microbiota, upregulating the relative abundance of Romboutsia, Turicibacter, and Clostridium_sensu_stricto_1 and downregulating the relative abundance of norank_f_Lachnospiraceae, suggesting that the clinical efficacy of Qingfei Paidu decoction might be related to the regulation of gut microbiota composition.

8.2. Regulation of the intestinal mucosal barrier to prevent bacterial translocation

In addition to influencing the composition and number of gut microbiota constituents, TCM can indirectly affect the positioning of the flora by protecting the intestinal mucosal barrier. The normal intestinal mucosal barrier effectively prevents intestinal bacteria and endotoxin from crossing the intestinal mucosa, avoiding gut-derived infection. A variety of single TCMs, Chinese herbal medicinal ingredients, and TCM preparations have been found to have significant protective effects on the intestinal mucosal barrier. A modern pharmacological study showed that Rheu radix et rhizoma can effectively block the cascade response of inflammatory mediators, reduce the number of intestinal Escherichia coli bacteria in severely infected rats, inhibit the expression of Toll-like receptor 2 (TLR2) and TLR4 mRNA, block the intestinal inflammatory response, maintain the function of the intestinal mucosal immune barrier, and inhibit the translocation of bacteria in the early stage of septicemia, with important therapeutic effects on acute lung injury [183]. Chang et al. [175] found that Ganoderma lucidum was able to protect the barrier function of the intestinal mucosa in mice, thus resisting the invasion of pathogenic microorganisms and preventing bacterial translocation. Fermented Yupingfeng polysaccharides (FYP) maintain intestinal barrier integrity and functionality by upregulating the mRNA levels of ZO-1, claudin, polyimmunoglobulin receptor, trefoil factor, and epidermal growth factor in the jejunum and ileum, achieving a protective effect on the mechanical and immune barriers of the intestinal mucosa [184]. Rheu radix et rhizoma can maintain intestinal mucosal immune barrier function by regulating the gut microbiota and suppressing intestinal inflammatory responses [183].

8.3. Regulating immunity

Recent studies have suggested that the causes of exacerbation and even death in viral infectious diseases such as COVID-19 are not only related to pulmonary viral infection but also closely related to immune dysfunction of the body [185,186]. Therefore, in the process of preventing and treating COVID-19, it is very important to improve the body’s own immune ability and regulate the immune balance. In addition to the direct or indirect antiviral effects of TCM in the prevention and treatment of COVID-19, the greatest advantage of TCM lies in its excellent immunomodulatory effects and reduced toxicity and side effects [187]. TCM has played an important role in the prevention and treatment of COVID-19. Among its effects, the immunomodulatory effect of TCM cannot be ignored. There have been many reports on the direct regulation of immunity by TCM, not only in the form of a single extracted ingredient or single Chinese medicine but also in the form of a compound prescription of TCM.

8.3.1. Single extracted ingredients of Chinese medicine regulate immunity

Poria Cocos polysaccharides [188] could improve immunity by reducing the content of IL-10 and regulating the secretion of Th1/Th2. Radix glycyrrhizae polysaccharides [189] could regulate cellular immunity disorders in tumour-bearing mice by decreasing the proportion of Treg cells and increasing the spleen lymphocyte transformation ratio. Bordbar et al. [190] found that glycyrrhizin could enhance the expression of the surface differentiation antigens CD80 and CD86 and the
Fig. 4. Mechanism of gut microbiota disorders induced by SARS-CoV-2 and the mechanism by which TCM regulates the gut microbiota to prevent and treat COVID-19. The binding of SARS-CoV-2 to the ACE2 receptor could reduce the expression of ACE2 and affect the absorption of tryptophan by small intestinal epithelial cells. It could also reduce the activity of the mTOR pathway in the small intestine and inhibit the expression of small intestinal antimicrobial peptides, leading to intestinal flora imbalance (a decrease in the number of beneficial bacteria and an increase in the number of harmful bacteria) and displacement, the destruction of the intestinal mucosal barrier, and an increase in intestinal endotoxins. The above process causes the excessive release of inflammatory mediators, the occurrence of endotoxaemia and cytokine storms, and tissue damage. In severe cases, ARDS and MODS can occur. However, TCM can help to suppress inflammatory storms and maintain the immune barrier function of the intestinal mucosa, thereby improving the body’s immunity and preventing the deterioration of the condition because of TCM’s ability to adjust the intestinal flora imbalance, promote the growth of beneficial bacteria, inhibit the excessive reproduction of harmful bacteria, and promote the production of SCFAs.
major histocompatibility complex II (MHC II) of dendritic cells (DCs), improve the production of IL-12, enhance the proliferation of allogeneic T cells, increase the expression of IFN-γ and IL-10, and regulate the Th1-type immune response. Forsythia leaf polysaccharides [191] could significantly increase the thymus index, spleen index, macrophage phagocytosis, spleen lymphocyte proliferation, serum IL-2 and IL-4 levels, haemolysin content, and number of haemolytic plaques in immunosuppressed mice induced by cyclophosphamide. Baicalein [192] could play an immunomodulatory role by balancing CD4+/CD8- and regulating the balance of T lymphocytes and their Th1/Th2 and Th17/Treg subsets. Chrysophanol [193] had an immunomodulatory effect in immunocompromised mice, which could enhance the proliferation of T and B lymphocytes, increase the spleen index and thymus index, upregulate the levels of serum IL-2 and IL-4, and promote an increase in haemolysin levels and the production of antibody cells. Flos Lonicerae polysaccharides [194] could regulate the immune function of immunosuppressed mice induced by cyclophosphamide, effectively increasing the organ index of the mice, enhancing the activity of NK cells and the phagocytosis of macrophages, promoting the proliferation of spleen lymphocytes, and enhancing the immunomodulatory activity of the immunosuppressed mice. In addition, Jia et al. [195] found that Flos Lonicerae polysaccharides could promote IFN-γ secretion by regulating immune function, stimulating an increase in the immune organ index and enhancing immune function. Liu et al. [196] found that Astragalus polysaccharides could improve the phagocytosis rate of macrophages and the spleen and thymus indices of mice.

3.8.2. Single Chinese medicines regulate immunity

Astragalus radix, Scutellariae radix, Isatidis radix, Pulsatilae radix, PolYGONI CUSPIDATI RHIZOMA ET RADIX, Herba hedysari, and Andrographis herba could regulate the balance of anti-inflammatory cytokines and proinflammatory cytokines in the lungs of mice infected with H1N1 influenza virus and then improve immune dysfunction, truncate the storm of cytokines, reduce the inflammatory injury of lung tissue, and promote the repair of inflammatory lesions of lung tissue [197–200]. Astragali radix [197] reduced the mRNA expression of the proinflammatory cytokines TNF-α, IL-1, and IL-6, significantly increased the mRNA expression of the anti-inflammatory cytokines IL-10 and IFN-γ in the lungs of mice, and significantly inhibited and repaired immune-inflammatory injury in lung tissue in mice. Scutellariae radix [198] inhibited the protein and gene expression of TNF-α, IL-1 and IL-6 in the lungs, promoted the protein and gene expression of IL-10 and IFN-γ, reduced the immune-inflammatory injury of lung tissue, and promoted the repair of inflammatory lesions in lung tissue. Isatidis radix, Pulsatilae radix, Polygoni cuspidati rhizoma et radix, and Herba hedysari can inhibit the expression of TNF-α, IL-1 and IL-6 and promote the expression of IL-10 and IFN-γ in the lung [199]. Andrographis herba [200] effectively regulated the concentrations of TNF-α, INF-γ and IL-10 in the peripheral blood of mice, increased the percentage of CD3+ T lymphocytes, regulated the ratio of CD4+/CD8- ratio, improved the cellular immune function of mice, and regulated the balance of proinflammatory and anti-inflammatory factors.

8.3.3. Chinese medicine compound prescriptions regulate immunity

Clinical studies have shown that Qingfei Paidu decoction can significantly improve the CD3+ and CD4+ cells counts of COVID-19 patients and enhance the body’s immune function [107,201]. Toujie Quwen capsules [180] could significantly increase the CD4+ and the ratio of CD4+/CD8+ in patients with COVID-19, promote the recovery of immune function and reduce the injury of cellular immunity. Lianhua Qingwen capsules [202] significantly inhibited the phosphorylation of p65 protein in the NF-κB pathway and significantly reduced the expression levels of TNF-α, IL-6, KC, MCP-1, IL-1β, and IP-10 in the lung tissue of H1N1-infected mice, suggesting that its immunomodulatory effect might be related to its inhibition of the NF-κB pathway. Jinhua Qinggan granules reduced the levels of serum CRP and IFN-γ in patients with influenza and improved immune function [203,204]. Xuebijing injection [205] reduced the levels of TNF-α and IL-6 in the lungs of mice infected with the influenza virus. In addition, clinical studies showed that, compared with human immunoglobulin alone, Xuebijing injection combined with human immunoglobulin could significantly shorten the antipyretic time, coughing, and asthma regression time and significantly reduce the levels of hs-CRP, IL-6, and TNF-α in patients with severe viral pneumonia [206]. Reducing injection [207,208] increased the level of IFN-γ in the lung tissue of virus-infected mice, decreased the levels of IL6 and TNF-α, decreased the levels of phosphorylated nuclear factor kappa B inhibitor protein (p-IκB) and NF-κB protein, decreased the expression of IL-1β mRNA and increased the gene expression of interferon-induced transmembrane protein 3 (IFITM3) and mitochondrial antiviral signal protein (MAVS). Tanreqing injection [209–211] could significantly improve the pathological injury of lung tissue in virus-infected mice, enhance the function of T and B lymphocytes, increase the content of IL-4 and IFN-γ in the lungs, downregulate the transcriptional activity of the transcription factor NF-κB, inhibit the content of TNF-α in the lungs, regulate the balance of Th1 and Th2 cells, reduce lung injury and corresponding inflammatory reactions, and enhance antiviral immune function. Buzhong Yiqi decoction [212] could significantly increase the serum CD3+ and CD4+ cell counts and the ratio of CD4+/CD8- in patients with recurrent respiratory tract infections and improve the immune function of patients. Maxing Shigan decoction [213] upregulated the body mass, spleen index, and thymus index of mice infected with influenza virus, reduced the levels of TNF-α, IL-1β, and IL-6 in the lungs, downregulated the expression of MyD88 and tumour necrosis factor receptor-associated protein 6 (TRAF6) mRNA and protein in lung tissue, increased the level of IL-2 in lung tissue and decreased the levels of IL-4 and TNF-α. Wang et al. [214] found that Sijunzi decoction could increase the levels of acetic acid, propionic acid, and butyric acid in the intestine; reduce the levels of the splenic index and serum inflammatory factors IL-2 and IFN-γ; and increase the ratio of CD-4+/CD-8+ in spleen-deficient mice, suggesting that Sijunzi decoction could increase the major SCFAs in the intestine and improve immunity in spleen-deficient rats.

8.4. Regulation of gut microbiota and its metabolites

The gut microbiota and their metabolites can affect the local or systemic immune function of the host. SCFAs are important products of dietary fibre fermentation by beneficial intestinal bacteria. The most common SCFAs are propionic acid, acetic acid, and butyric acid, with Bacteroides producing mainly propionic acid and acetic acid and Firmicutes producing mainly butyrate [215]. SCFAs not only have an important function in the metabolism of the body but also play a role in regulating inflammation and immune homeostasis [216]. Immunomodulatory effects associated with SCFAs include enhancing the barrier function of intestinal epithelial cells, reducing the induction of proinflammatory cytokines, stimulating the production of regulatory T cells, promoting intestinal mucosal homeostasis, preventing colonic inflammation, and enhancing the proinflammatory state of intestinal epithelial cells and leukocytes [217,218]. SCFAs can induce the production and differentiation of regulatory T cells, promoting the production of the anti-inflammatory cytokine IL-10, and they can strongly reduce the release of the proinflammatory chemokines CCL3, CCL4, CCL5, CXCL9, CXCL10, and CXCL11, thereby inhibiting leukocyte migration with a strong anti-inflammatory effect [219]. Studies have found that Firmicutes is an important source of butyrate, which is a major energy substrate for cells. The decrease in the ratio of Firmicutes to Bacteroides could directly affect the metabolism of dietary fibre by the gut microbiota, resulting in lower concentrations of SCFAs, and the decrease in Firmicutes could induce or exacerbate local inflammatory responses [220]. Prevotella, Ruminococcus, Coprococcus, Clostridium butyricum, and Lactobacillus all increase the content of SCFAs in the intestine, induce the production and differentiation of regulatory T cells in the intestine of
mice, promote IL-10 production, and exert inflammatory inhibitory effects [221–223]. In contrast, overgrown *Escherichia coli* or * Klebsiella pneumonia* could promote the expression of chemokines such as CCL5 and CXCL10, thereby aggravating the degree of inflammatory injury [224]. A previous study showed that influenza A virus infection could cause structural disorders of the gut microbiota and immune dysfunction in mice, and Maxinghian decocction had a protective effect against influenza virus-induced intestinal immune damage by upregulating the relative abundance of *Firmicutes*, *Lactobacillus*, and *Coprooccus* and downregulating the relative abundance of *Proteobacteria* and *Escherichia*, regulating the structure of the gut microbiota and affecting the production of chemokines [225]. Other studies have indicated that Chinese medicine could increase the production of SCFAs by modulating the gut microbiota to improve the barrier function of the intestine and inhibit the inflammatory response of the intestinal mucosa [179,226]. Zhang et al. [227] reported that Shenling Baizhu powder could increase the relative abundance of SCFA-producing bacteria (including *Bifidobacterium* and *Bacteroides*) in the intestine of obese rats, reduce the levels of serum endotoxin, TNF-α, and IL-1β, and reduce systemic inflammation. TCM regulates the gut microbiota to prevent and treat COVID-19, as shown in Fig. 4.

9. Conclusions and prospects

In the prevention and control of this epidemic, early intervention, full participation, and classified treatment of TCM have made important and lasting contributions to the comprehensive control of the COVID-19 epidemic. Clinical studies have confirmed that TCM has certain advantages in improving the clinical symptoms of COVID-19 patients, inhibiting the storm of inflammatory factors, promoting the absorption of pulmonary inflammation, shortening the course of treatment, and promoting recovery. Currently, the focus and difficulties in the treatment of COVID-19 concern mainly the more severe and critical cases, which are also the main factors directly affecting mortality [27]. There is no definite and effective treatment for the more severe and critical COVID-19 patients in modern medicine, but the intervention of TCM or integrated traditional Chinese and Western medicine according to the clinical symptoms of the more severe and critical COVID-19 patients can help to reduce mortality and improve prognosis [22,25,27,228]. The gut microbiota in severe and critical COVID-19 patients is disordered, rendering it prone to bacterial infection and further aggravating the disease. Therefore, it is essential to maintain the balance of the gut microbiota.

There are many relationships between the gut microbiota and COVID-19. On the one hand, COVID-19 patients have gut microbiota disorders and intestinal barrier function damage; on the other hand, the gut microbiota can regulate the local and systemic immune system, becoming the turning point of the prognosis of the disease. Therefore, restoring and regulating the balance of gut microbiota are helpful for the rehabilitation of COVID-19 patients. In the Guideline on Diagnosis and Treatment of COVID-19 (trial 8th edition) [15], formulated by the National Health Commission of the People’s Republic of China, it is mentioned that, for more severe and critical COVID-19 patients, microecological regulators should be selected in a timely and reasonable manner to restore and maintain intestinal homeostasis and prevent bacterial infection. In addition, the ‘four antibiotics and two balances’ suggested by the academician Lanjuan Li, that is, anti-virus, anti-shock, anti-hypoxiaemia, anti-secondary infection, maintaining water-electrolyte acid-base balance and microecological balance, also clearly indicate the importance of using microecological agents to maintain the balance of intestinal bacteria in improving patients’ immunity and preventing secondary infection. TCM plays a positive role in promoting the diagnoses of patients with coronavirus infection or COVID-19 by maintaining the dynamic balance between the type and number of the gut microbiota and improving body immunity, but its mechanism remains to be further elucidated. From the perspective of TCM, research on maintaining the gut microbiota balance and correcting gut microbiota imbalances and finding new targets and new ideas for the treatment of COVID-19, whether for the treatment of the sick or the health care of the undisposed, are of great significance.

**CRediT authorship contribution statement**

Shuping Wang was responsible for the entire manuscript; Zhihua Yang, Yangxi Liu, Lin Wang and Shanshan Lin conceived, designed, wrote and revised the manuscript; Zhihua Yang and Yangxi Liu have contributed equally to this work and shared first authorship; Xianrong Dai, Haifeng Yan contributed to draw diagram; Zhao Ge, Quan Ren, Hui Wang, Feng Zhu revised the manuscript and discussed interpretation. All authors have read and approved the final submission.

**Conflict of interest statement**

The authors declare that there are no conflicts of interest.

**Acknowledgments**

The study was supported by the Tianjin Research Innovation Project for Postgraduate Students (No. 2021YSJB294) and Graduate Research innovation project of Tianjin University of Traditional Chinese Medicine (No. YJSKC-20211012).

**References**

[1] C. Wang, P.W. Horby, F.G. Hayden, G.F. Gao, A novel coronavirus outbreak of global health concern, Lancet 395 (10223) (2020) 470–473.
[2] A.E. Gorbalenya, S.C. Baker, R.S. Baric, R.J. de Groot, C. Drosten, A.A. Gulyaeva, B.L. Haagmans, C. Lauwere, A.M. Leontovich, B.W. Neuman, D. Penzar, S. Perlman, L.M. Poon, D. Samborskiy, I.A. Sidirov, I. Sola, J. Ziebuehr, Severe acute respiratory syndrome-related coronavirus: the species and its viruses – a statement of the coronavirus study group, bioRxiv (2020). [https://www.biorxiv.org/content/10.1101/2020.02.07.937862v1].
[3] WHO, Novel Coronavirus (2019-nCoV) Situation Report-22 [EB/OL], 2020. [https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports/].
[4] WHO, Statement on the Second Meeting of the International Health Regulations (2005) Emergency Committee Regarding the Outbreak of Novel Coronavirus (2019-nCoV), 2020. [https://www.who.int/news-room/detail/30-01-2020-statement-on-the-second-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-outbreak-of-novel-coronavirus-(2019-ncov)] (Accessed 28 April 2020).
[5] World Health Organization, Novel Coronavirus (2019-nCoV) [EB/OL]. [https://www.who.int/emergencies/diseases/novel-coronavirus-2019].
[6] M. Li, F. Lou, H. Fan, SARS-CoV-2 variants of concern delta: a great challenge to prevention and control of COVID-19, Signal Transduc. Target. Ther. 6 (1) (2021) 349.
[7] A. Hakim, M.M. Hasan, M. Hasan, S.M. Lokman, K.F. Azim, T. Ralhan, P.A. Chowdhury, A.K. Arad, Major insights in dynamics of host response to SARS-CoV-2: impacts and challenges, Front. Microbiol. 12 (2021) 637554.
[8] Z. Ren, H. Wang, G. Cai, H. Lu, L. Wang, H. Luo, X. Chen, H. Ren, R. Sun, W. Liu, X. Liu, C. Liu, A. Li, X. Wang, B. Rao, C. Yuan, H. Zhang, J. Sun, X. Chen, B. Li, C. Hu, Z. Wu, Z. Yu, Q. Kan, L. Li, Alterations in the human oral and gut microbiomes and lipopolysaccharides in COVID-19, Gut 70 (7) (2021) 1253–1265.
[9] X. Jin, J.S. Lian, J.H. Hui, J. Gao, L. Zhang, Y.M. Zhang, S.R. Hao, H.Y. Jia, H. Cai, X.L. Zhang, G.D. Yu, K.J. Xu, X.Y. Wang, J.G. Su, Z.Y. Zhang, C.Y. Ye, C.L. Jin, Y. Fu, L. Xu, Y. Yu, X.P. Yu, J.R. Huang, K.L. Xu, Q. Ni, C.B. Yu, B. Zhu, Y.T. Li, J. Liu, H. Zhao, X. Zhang, L. Lu, Y.Z. Guo, J.W. Su, J.J. Tao, G.J. Lang, X.X. Wu, W. R. Wu, T.T. Qv, D.R. Xiang, P. Li, D. Shi, Y. Chen, Y. Ren, Y.Q. Qiu, L.J. Li, J. Sheng, Y. Yang, Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms, Gut 69 (6) (2020) 1002–1009.
[10] M. Du, G. Cai, F. Chen, D.C. Christiani, Z. Zhang, M. Wang, Multitumors malignation of gastrointestinal and other clinical characteristics of COVID-19, Gastroenterology 158 (8) (2020) 2289–2301, c7.
[11] L. Tang, S. Gu, Y. Gong, B. Li, H. Lu, Q. Li, R. Zhang, X. Gao, Z. Wu, J. Zhang, Y. Zhang, L. Li, Clinical significance of the correlation between changes in the major intestinal bacteria species and COVID-19 severity, Engineering 6 (10) (2020) 1178–1184.
[12] Y.Y. Yeoh, T. Zuo, G.C. Lui, F. Zhang, Q. Liu, A.Y. Li, A.C. Chung, C.P. Chung, E. Y. Tao, K.S. Fung, V. Chan, L. Ling, G. Joynt, D.S. Hui, K.M. Chow, S.S.S. Ng, T. L.L.M. Poon, D. Samborskiy, I.A. Sidirov, I. Sola, J. Ziebuehr, Severe acute respiratory syndrome-related coronavirus: the species and its viruses – a statement of the coronavirus study group, bioRxiv (2020). [https://www.biorxiv.org/content/10.1101/2020.02.07.937862v1].
cardiovascular and cerebrovascular diseases in 124 cases, J. Tradit. Chin. Med. 62 (2021) 1714–1717.

W. Xiong, G. Wang, J. Du, W. Al, Efficacy of herbal medicine (Xuanfei Baidu Decoction) combined with conventional drug in treating COVID-19:A pilot randomized clinical trial, Integr. Med. Res. 9 (3) (2020), 104897.

J. Liu, W. Yang, Y. Liu, C. Lu, Luan, C. Zhao, R. Huo, X. Sheng, Qiao, W. Lv, L. Hi, H. Li, H. Lu, Z. Zhang, Y. Zhang, L. Wang, B. Wang, G. Dong, Y. Xian, B. Li, Li, Z. Zhou, C. Fu, Y. Chen, S. Wu, Q. Guo, J. Yang, W. Wang, J. Li, X. Xie, M. Xu, M. Ji, J. Zhang, G. Wang, X. Cong, H. Zhu, J. Shi, L. Leng, D. Li, L. Guo, L. Huang, Combination of Hua Shi Bai Du granule (Q-14) and standard care in the treatment of patients with coronavirus disease 2019 (COVID-19): A single-center, open-label, randomized controlled trial, Phytomedicine 91 (2021), 153671.

T.F. Shi, G.C. Zhou, L.Y. Zhang, F. Niu, Y.C. Ke, T. Zhou, Q.S. Wang, X.J. Jin, D. Liu, B.J. Wei, W.Q. Zhang, Z.M. Zhang, Y.Q. Li, Clinical efficacy of Xuanfu Huaxiao prescription on 40 cases of COVID-19, Chin. J. Exp. Tradit. Med. 36 (2020) 26–31.

M.W. Yang, F. Chen, D.J. Zhu, J.Z. Li, J.L. Zhu, W. Zeng, S.L. Qu, Y. Zhang, Clinical efficacy of macrine and sodium chloride injection in treatment of 40 cases of COVID-19, China J. Chin. Mater. Med. 45 (10) (2020).

L.W. Wang, W.N. Li, W. Huang, Z.M. Zhong, Y.L. Deng, Y.L. Hu, R. Tao, X.H. Zuo, Y. Feng, D.B. Lu, B.B. Yu, Clinical study of Qigian pill in preventing COVID-19, World Sci Tech-Mod. Tradit. Chin. Med. 22 (10) (2020) 3509–3514.

X. Yang, S. Zhang, Z.M. Zhang, D.Z. Su, Combined clinical efficicncy of Xuanfei Baidu decoction combined with western medicine in 43 cases and single western medicine in 46 cases in the treatment of COVID-19, J. Shandong Univ. Health Sci. 19, World Sci Tech-Mod. Tradit. Chin. Med. 22 (10) (2020) 3509–3514.

Z. Yang et al.

Clinical efficacy of matrine and sodium chloride injection in treatment of 40 cases of COVID-19, Chin. J. Exp. Tradit. Med. 26 (16) (2020) 26–31.

M.W. Yang, F. Chen, D.J. Zhu, J.Z. Li, J.L. Zhu, W. Zeng, S.L. Qu, Y. Zhang, Clinical efficacy of macrine and sodium chloride injection in treatment of 40 cases of COVID-19, China J. Chin. Mater. Med. 45 (10) (2020).

L.W. Wang, W.N. Li, W. Huang, Z.M. Zhong, Y.L. Deng, Y.L. Hu, R. Tao, X.H. Zuo, Y. Feng, D.B. Lu, B.B. Yu, Clinical study of Qigian pill in preventing COVID-19, World Sci Tech-Mod. Tradit. Chin. Med. 22 (10) (2020) 3509–3514.

X. Yang, S. Zhang, Z.M. Zhang, D.Z. Su, Combined clinical efficicncy of Xuanfei Baidu decoction combined with western medicine in 43 cases and single western medicine in 46 cases in the treatment of COVID-19, J. Shandong Univ. Health Sci. 19, World Sci Tech-Mod. Tradit. Chin. Med. 22 (10) (2020) 3509–3514.

Z. Yang et al.

Clinical efficacy of matrine and sodium chloride injection in treatment of 40 cases of COVID-19, Chin. J. Exp. Tradit. Med. 26 (16) (2020) 26–31.

M.W. Yang, F. Chen, D.J. Zhu, J.Z. Li, J.L. Zhu, W. Zeng, S.L. Qu, Y. Zhang, Clinical efficacy of macrine and sodium chloride injection in treatment of 40 cases of COVID-19, China J. Chin. Mater. Med. 45 (10) (2020).

L.W. Wang, W.N. Li, W. Huang, Z.M. Zhong, Y.L. Deng, Y.L. Hu, R. Tao, X.H. Zuo, Y. Feng, D.B. Lu, B.B. Yu, Clinical study of Qigian pill in preventing COVID-19, World Sci Tech-Mod. Tradit. Chin. Med. 22 (10) (2020) 3509–3514.

X. Yang, S. Zhang, Z.M. Zhang, D.Z. Su, Combined clinical efficicncy of Xuanfei Baidu decoction combined with western medicine in 43 cases and single western medicine in 46 cases in the treatment of COVID-19, J. Shandong Univ. Health Sci. 19, World Sci Tech-Mod. Tradit. Chin. Med. 22 (10) (2020) 3509–3514.
36

S. Perlman, Another decade, another coronavirus, N. Engl. J. Med. 382 (8) (2020) 760-762.

V.J. Munster, M. Koopmans, N. van Doremalen, D. van Riel, E. de Wit, A. Novel, Coronavirus emerging in China - key questions for impact assessment, N. Engl. J. Med. 382 (8) (2020) 692-694.

W. Li, M.J. Moore, N. Van sleuven, J. Sui, S.K. Wang, M.A. Berne, M. Somasundaran, J.L. Sullivan, K. Lucey, T.C. Greenough, H. Choe, M. Farzan, Angiotensin converting enzyme 2 is a functional receptor for the SARS coronavirus, Nature 426 (6965) (2003) 450-454.

X.Y. Ge, J.L., Li, X.Y. Song, A.A. Chmura, G.Z. Zhu, J.H. Epstein, J.K. Maetz, B. Hu, W. Zhang, C. Peng, Y.J. Zhang, C.M. Luo, B. Tan, N. Wang, Y. Zhu, G. Cramerle, S.Y. Zhang, L.F. Wang, P. Daskas, Z.L. Shi, Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor, Nature 503 (7477) (2013) 727-733.

M. Wang, Z. Hu, Rats as animal reservoirs for the SARS coronavirus: hypothesis proved after 10 years of virus hunting, Virol. Sin. 26 (8) (2011) 315-317.

C. Huang, Y. Wang, X. Li, L. Ren, J. Zhao, Y. Hu, L. Zhang, G. Fan, J. Xu, X. Gu, Z. Cheng, Y. Xue, J. Xin, Y. Wei, W. Wu, X. Yin, H. Li, M. Liu, Y. Xiao, H. Gao, L. Guo, J. Jie, X. Gie, Wang, R. Jiang, Z. Gao, Q. Jin, J. Wang, B. Cao, Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet 395 (10223) (2020) 497-506.

X. Zou, K. Chen, J. Zou, P. Han, J. Hao, Z. Han, Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection, Front. Med. 14 (2) (2020) 185-192.

N. Zhu, D. Zhang, W. Wang, X. Li, B. Yang, J. Song, X. Zhao, B. Huang, W. Shi, R. Lu, P. Niu, F. Yang, M. Ma, D. Wang, X.W. Wu, G.W. Guo, G. Wang, Novel Coronavirus Investigating and Research Team, A novel coronavirus from patients with pneumonia in China, 2019, N. Engl. J. Med. 382 (8) (2020) 727-733.

H. Zhang, Z. Zhang, H. Gong, D. Xu, H. Xu, Digestive system is a potential route of infection for 2019-nCoV, Cell Physiol. Biochem. 425 (6002) (2020) 1035-1040.

R. Cao, X. Li, X. Li, X. Chen, P. Yang, Z. Yang, F. Liu, L. Zhang, S. Wang, J. Lin, X. Tian, Y. Shi, Q. Han, L. Zhang, W. Zhou, X. Fan, J. Man, Y. Li, J. Li, Y. Liu, W. Liu, X. Yin, The cytokine storm of severe influenza and the risk for death, Crit. Care 23 (1) (2019) 195.

R.P. Dickson, B.H. Singer, M.M. Newstead, N.R. Falkowski, J.R. Erb-Downward, T.J. Clarkson, G. Fontenot, Enrichment of the lung microbiome by chemoattraction of gut bacteria in sepsis and the respiratory distress syndrome, Nat. Microbiol. 1 (10) (2016) 16113.
Z. Yang et al.

Effect of Xuebijing Injection combined with severe pneumonia by Xuebijing injection, World Chin. Med. 10 (02) (2018) 1664–1669.

Effects of shenling baizhu powder herbal formula on intestinal microbiota in high-fat diet-induced ulcerative colitis rats by modulating the composition of the gut microbiota, short chain fatty acids levels and GPR41/43 receptors, Int. J. Mol. Sci. 21 (6) (2020) 1637–1645.

L. Zheng, L.G. Gu, Study on anti-virus effect of Tanreqing injection on the influence of influenza virus FM1 infected mice, China J. Infect. Dis. 4 (12) (2016) 1664–1669.

Z.Y. Kho, S.K. Lai, The human gut microbiome – a potential controller of wellness and disease, Front. Microbiol. 9 (2018) 1835.

A. Koh, F. De Vadder, P. Kovatcheva-Datchary, F. Backhed, From dietary fiber to host physiology: short chain fatty acids as key bacterial metabolites, Cell 165 (6) (2016) 1332–1345.

P. Louis, G.L. Hold, H.J. Flint, The gut microbiome, bacterial metabolites and colorectal cancer, Nat. Rev. Microbiol. 12 (10) (2014) 661–672.

H.N. Yu, Z.H. Liu, Recent progress in intestinal microbiota and mucosal immunity, Chin. J. Immunol. 35 (16) (2019) 1921–1930.

S. Shao, D.W. Wang, W. Zheng, X. Li, H. Zhang, D. Zhao, M. Wang, A unique polysaccharide from Hericium erinaceus mycelium ameliorates acetic acid-induced ulcerative colitis rats by modulating the composition of the gut microbiota, short chain fatty acids levels and GP-R41/43 receptors, Int. Immunopharmacol. 71 (2019) 411–422.